[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fpxG0D81JyYI6KoQHHP6pLI0MirupdEE9ltusEUY1BT4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":82,"rows":89},"University of California, Irvine",[4],463,false,113,9,537085,76,329,[14,17,19,21,23,26,28,30],{"name":15,"count":16},"Breast Cancer",13,{"name":18,"count":9},"Cancer",{"name":20,"count":9},"Port Wine Stain",{"name":22,"count":9},"Prostate Cancer",{"name":24,"count":25},"Cervical Cancer",6,{"name":27,"count":25},"Port-Wine Stain",{"name":29,"count":25},"Lung Cancer",{"name":31,"count":25},"Colorectal Cancer",[33,38,43,48,53,58,63,68,72,77],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT02436993","Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab","2023-11","Carboplatin",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT04164979","Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma","2023-11-25","Cabozantinib",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT04231851","CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia","2024-06-30","Glasdegib",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT05488366","Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma","2025-06-27","Pembrolizumab",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT03977207","A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients","2025-11-30","Levothyroxine Sodium",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT07281781","Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow","2026-06","Nelfinavir",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT04472767","Cabozantinib Combined With Ipilimumab\u002FNivolumab and TACE in Patients With Hepatocellular Carcinoma","2026-06-01","Nivolumab",{"nctId":69,"briefTitle":70,"date":66,"intervention":71},"NCT05169814","Micro\u002FNanobubbles (MNBs) for Treatment of Acute and Chronic Wounds","Micro\u002Fnanobubble (MNB) - Irrigation",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT05334329","Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and\u002For PD-L1 Immune Checkpoint Inhibitors","2026-06-14","Antineoplastic Immune Cell",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT06112353","Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection","2026-07","Neostigmine Injectable Solution",[83,84,85,86,87,88],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[90,134,173,199,228,246,264,292,310,328,351,369,387,405,423,449,478,496,514,542,605,646,707,747,782,813,843,883,922,948,986,1008,1031,1060,1084,1102,1128,1146,1164,1188,1213,1231,1249,1279,1297,1315,1338,1361,1379,1397,1415,1433,1454,1485,1532,1558,1601,1619,1637,1655,1673,1691,1709,1727,1745,1763,1787,1805,1830,1855,1873,1896,1914,1948,1966,1992,2010,2048,2074,2106,2133,2151,2169,2198,2216,2234,2252,2279,2297,2315,2341,2365,2383,2407,2432,2457,2484,2502,2528,2546,2573,2598,2616,2634,2660,2684,2707,2733,2751,2790,2818,2850,2884,2912,2945,2969,2993,3016,3042,3066,3084,3102,3120,3149,3172,3199,3217,3235,3262,3280,3306,3329,3352,3376,3399,3423,3441,3465,3483,3509,3527,3545,3573,3596,3614,3636,3659,3683,3701,3722,3746,3764,3787,3805,3829,3853,3876,3898,3922,3947,3972,3994,4020,4038,4062,4096,4121,4143,4165,4191,4209,4236,4254,4277,4303,4328,4351,4374,4398,4422,4446,4468,4495],{"intervention":91,"totalTrials":92,"cells":93},"Topiramate",2,{"EARLY_PHASE1":94,"PHASE1":97,"PHASE2":99,"PHASE3":101,"PHASE4":103,"NA":132},{"trials":95,"activeCount":96},[],0,{"trials":98,"activeCount":96},[],{"trials":100,"activeCount":96},[],{"trials":102,"activeCount":96},[],{"trials":104,"activeCount":92,"soonestReadout":123},[105,118],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":116},"NCT05975580","Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery","RECRUITING",[87],"2027-04-30","2027-07-31","2023-08-29",120,[115],"Obesity",[91,117],"Phentermine",{"nctId":119,"briefTitle":120,"status":121,"phases":122,"primaryCompletion":123,"completion":123,"start":124,"enrollment":125,"conditions":126,"interventions":128},"NCT06799169","Management of Acute Tinnitus With Migraine Medications","ACTIVE_NOT_RECRUITING",[87],"2026-12","2025-06-01",100,[127],"Tinnitus",[129,91,130,131],"Nortriptyline","Paroxetine","Verapamil",{"trials":133,"activeCount":96},[],{"intervention":135,"totalTrials":92,"cells":136},"Nortriptyline + Topiramate",{"EARLY_PHASE1":137,"PHASE1":139,"PHASE2":141,"PHASE3":143,"PHASE4":145,"NA":171},{"trials":138,"activeCount":96},[],{"trials":140,"activeCount":96},[],{"trials":142,"activeCount":96},[],{"trials":144,"activeCount":96},[],{"trials":146,"activeCount":170,"soonestReadout":163},[147,159],{"nctId":148,"briefTitle":149,"status":150,"phases":151,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":155,"interventions":157},"NCT04404439","Treatment of Tinnitus With Migraine Medications","COMPLETED",[87],"2023-12-30","2019-09-26",78,[156,127],"Tinnitus, Subjective",[135,158],"Verapamil + Paroxetine",{"nctId":160,"briefTitle":161,"status":108,"phases":162,"primaryCompletion":163,"completion":163,"start":164,"enrollment":165,"conditions":166,"interventions":168},"NCT05582837","Treatment of Meniere's Disease With Migraine Medications",[87],"2027-12-30","2022-08-01",40,[167],"Ménière",[169],"nortriptyline + topiramate",1,{"trials":172,"activeCount":96},[],{"intervention":174,"totalTrials":170,"cells":175},"Lovenox",{"EARLY_PHASE1":176,"PHASE1":178,"PHASE2":180,"PHASE3":182,"PHASE4":184,"NA":197},{"trials":177,"activeCount":96},[],{"trials":179,"activeCount":96},[],{"trials":181,"activeCount":96},[],{"trials":183,"activeCount":96},[],{"trials":185,"activeCount":170,"soonestReadout":190},[186],{"nctId":187,"briefTitle":188,"status":108,"phases":189,"primaryCompletion":190,"completion":111,"start":191,"enrollment":192,"conditions":193,"interventions":196},"NCT04861103","Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)",[87],"2026-12-31","2020-10-01",12,[194,195],"Pregnancy, High Risk","Anticoagulants",[174],{"trials":198,"activeCount":96},[],{"intervention":200,"totalTrials":170,"cells":201},"Oral furosemide",{"EARLY_PHASE1":202,"PHASE1":204,"PHASE2":206,"PHASE3":208,"PHASE4":210,"NA":226},{"trials":203,"activeCount":96},[],{"trials":205,"activeCount":96},[],{"trials":207,"activeCount":96},[],{"trials":209,"activeCount":96},[],{"trials":211,"activeCount":170,"soonestReadout":217},[212],{"nctId":213,"briefTitle":214,"status":215,"phases":216,"primaryCompletion":217,"completion":217,"start":218,"enrollment":219,"conditions":220,"interventions":224},"NCT07167862","Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound","NOT_YET_RECRUITING",[87],"2028-06-15","2026-06-15",96,[221,222,223],"Preeclampsia","Preeclampsia Postpartum","Preeclampsia Severe or Mild",[200,225],"Intravenous furosemide",{"trials":227,"activeCount":96},[],{"intervention":225,"totalTrials":170,"cells":229},{"EARLY_PHASE1":230,"PHASE1":232,"PHASE2":234,"PHASE3":236,"PHASE4":238,"NA":244},{"trials":231,"activeCount":96},[],{"trials":233,"activeCount":96},[],{"trials":235,"activeCount":96},[],{"trials":237,"activeCount":96},[],{"trials":239,"activeCount":170,"soonestReadout":217},[240],{"nctId":213,"briefTitle":214,"status":215,"phases":241,"primaryCompletion":217,"completion":217,"start":218,"enrollment":219,"conditions":242,"interventions":243},[87],[221,222,223],[200,225],{"trials":245,"activeCount":96},[],{"intervention":117,"totalTrials":170,"cells":247},{"EARLY_PHASE1":248,"PHASE1":250,"PHASE2":252,"PHASE3":254,"PHASE4":256,"NA":262},{"trials":249,"activeCount":96},[],{"trials":251,"activeCount":96},[],{"trials":253,"activeCount":96},[],{"trials":255,"activeCount":96},[],{"trials":257,"activeCount":170,"soonestReadout":110},[258],{"nctId":106,"briefTitle":107,"status":108,"phases":259,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":260,"interventions":261},[87],[115],[91,117],{"trials":263,"activeCount":96},[],{"intervention":265,"totalTrials":170,"cells":266},"4% Chlorhexidine Gluconate",{"EARLY_PHASE1":267,"PHASE1":269,"PHASE2":271,"PHASE3":273,"PHASE4":275,"NA":290},{"trials":268,"activeCount":96},[],{"trials":270,"activeCount":96},[],{"trials":272,"activeCount":96},[],{"trials":274,"activeCount":96},[],{"trials":276,"activeCount":170,"soonestReadout":281},[277],{"nctId":278,"briefTitle":279,"status":108,"phases":280,"primaryCompletion":281,"completion":282,"start":283,"enrollment":284,"conditions":285,"interventions":287},"NCT05586776","Decolonization to Reduce After-Surgery Events of Surgical Site Infection",[87],"2027-01","2028-12","2023-01-17",2700,[286],"Surgical Site Infection",[265,288,289],"2% Mupirocin","Soap Without Antiseptic Properties",{"trials":291,"activeCount":96},[],{"intervention":288,"totalTrials":170,"cells":293},{"EARLY_PHASE1":294,"PHASE1":296,"PHASE2":298,"PHASE3":300,"PHASE4":302,"NA":308},{"trials":295,"activeCount":96},[],{"trials":297,"activeCount":96},[],{"trials":299,"activeCount":96},[],{"trials":301,"activeCount":96},[],{"trials":303,"activeCount":170,"soonestReadout":281},[304],{"nctId":278,"briefTitle":279,"status":108,"phases":305,"primaryCompletion":281,"completion":282,"start":283,"enrollment":284,"conditions":306,"interventions":307},[87],[286],[265,288,289],{"trials":309,"activeCount":96},[],{"intervention":289,"totalTrials":170,"cells":311},{"EARLY_PHASE1":312,"PHASE1":314,"PHASE2":316,"PHASE3":318,"PHASE4":320,"NA":326},{"trials":313,"activeCount":96},[],{"trials":315,"activeCount":96},[],{"trials":317,"activeCount":96},[],{"trials":319,"activeCount":96},[],{"trials":321,"activeCount":170,"soonestReadout":281},[322],{"nctId":278,"briefTitle":279,"status":108,"phases":323,"primaryCompletion":281,"completion":282,"start":283,"enrollment":284,"conditions":324,"interventions":325},[87],[286],[265,288,289],{"trials":327,"activeCount":96},[],{"intervention":81,"totalTrials":170,"cells":329},{"EARLY_PHASE1":330,"PHASE1":332,"PHASE2":334,"PHASE3":336,"PHASE4":338,"NA":349},{"trials":331,"activeCount":96},[],{"trials":333,"activeCount":96},[],{"trials":335,"activeCount":96},[],{"trials":337,"activeCount":96},[],{"trials":339,"activeCount":170,"soonestReadout":80},[340],{"nctId":78,"briefTitle":79,"status":108,"phases":341,"primaryCompletion":80,"completion":342,"start":343,"enrollment":344,"conditions":345,"interventions":347},[87],"2026-07-31","2024-04-17",128,[346],"Intestinal Disease",[81,348],"Sugammadex",{"trials":350,"activeCount":96},[],{"intervention":348,"totalTrials":170,"cells":352},{"EARLY_PHASE1":353,"PHASE1":355,"PHASE2":357,"PHASE3":359,"PHASE4":361,"NA":367},{"trials":354,"activeCount":96},[],{"trials":356,"activeCount":96},[],{"trials":358,"activeCount":96},[],{"trials":360,"activeCount":96},[],{"trials":362,"activeCount":170,"soonestReadout":80},[363],{"nctId":78,"briefTitle":79,"status":108,"phases":364,"primaryCompletion":80,"completion":342,"start":343,"enrollment":344,"conditions":365,"interventions":366},[87],[346],[81,348],{"trials":368,"activeCount":96},[],{"intervention":129,"totalTrials":170,"cells":370},{"EARLY_PHASE1":371,"PHASE1":373,"PHASE2":375,"PHASE3":377,"PHASE4":379,"NA":385},{"trials":372,"activeCount":96},[],{"trials":374,"activeCount":96},[],{"trials":376,"activeCount":96},[],{"trials":378,"activeCount":96},[],{"trials":380,"activeCount":170,"soonestReadout":123},[381],{"nctId":119,"briefTitle":120,"status":121,"phases":382,"primaryCompletion":123,"completion":123,"start":124,"enrollment":125,"conditions":383,"interventions":384},[87],[127],[129,91,130,131],{"trials":386,"activeCount":96},[],{"intervention":130,"totalTrials":170,"cells":388},{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":393,"PHASE3":395,"PHASE4":397,"NA":403},{"trials":390,"activeCount":96},[],{"trials":392,"activeCount":96},[],{"trials":394,"activeCount":96},[],{"trials":396,"activeCount":96},[],{"trials":398,"activeCount":170,"soonestReadout":123},[399],{"nctId":119,"briefTitle":120,"status":121,"phases":400,"primaryCompletion":123,"completion":123,"start":124,"enrollment":125,"conditions":401,"interventions":402},[87],[127],[129,91,130,131],{"trials":404,"activeCount":96},[],{"intervention":131,"totalTrials":170,"cells":406},{"EARLY_PHASE1":407,"PHASE1":409,"PHASE2":411,"PHASE3":413,"PHASE4":415,"NA":421},{"trials":408,"activeCount":96},[],{"trials":410,"activeCount":96},[],{"trials":412,"activeCount":96},[],{"trials":414,"activeCount":96},[],{"trials":416,"activeCount":170,"soonestReadout":123},[417],{"nctId":119,"briefTitle":120,"status":121,"phases":418,"primaryCompletion":123,"completion":123,"start":124,"enrollment":125,"conditions":419,"interventions":420},[87],[127],[129,91,130,131],{"trials":422,"activeCount":96},[],{"intervention":424,"totalTrials":170,"cells":425},"Suzetrigine",{"EARLY_PHASE1":426,"PHASE1":428,"PHASE2":430,"PHASE3":432,"PHASE4":434,"NA":447},{"trials":427,"activeCount":96},[],{"trials":429,"activeCount":96},[],{"trials":431,"activeCount":96},[],{"trials":433,"activeCount":96},[],{"trials":435,"activeCount":170,"soonestReadout":441},[436],{"nctId":437,"briefTitle":438,"status":439,"phases":440,"primaryCompletion":441,"completion":441,"start":442,"enrollment":443,"conditions":444,"interventions":446},"NCT07145346","Suzetrigine for Acute Pain Control in Patients With Multiple Rib Fractures","ENROLLING_BY_INVITATION",[87],"2027-08","2025-11-13",80,[445],"Rib Fractures",[424],{"trials":448,"activeCount":96},[],{"intervention":450,"totalTrials":170,"cells":451},"Estring Vaginal Product",{"EARLY_PHASE1":452,"PHASE1":454,"PHASE2":456,"PHASE3":458,"PHASE4":460,"NA":476},{"trials":453,"activeCount":96},[],{"trials":455,"activeCount":96},[],{"trials":457,"activeCount":96},[],{"trials":459,"activeCount":96},[],{"trials":461,"activeCount":170,"soonestReadout":466},[462],{"nctId":463,"briefTitle":464,"status":121,"phases":465,"primaryCompletion":466,"completion":467,"start":468,"enrollment":469,"conditions":470,"interventions":473},"NCT06353269","Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections",[87],"2027-06","2027-09","2024-06-14",111,[471,472],"Recurrent Urinary Tract Infection","Hypoestrogenism",[450,474,475],"Vagifem","Estrace 0.01% Vaginal Cream",{"trials":477,"activeCount":96},[],{"intervention":474,"totalTrials":170,"cells":479},{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":486,"PHASE4":488,"NA":494},{"trials":481,"activeCount":96},[],{"trials":483,"activeCount":96},[],{"trials":485,"activeCount":96},[],{"trials":487,"activeCount":96},[],{"trials":489,"activeCount":170,"soonestReadout":466},[490],{"nctId":463,"briefTitle":464,"status":121,"phases":491,"primaryCompletion":466,"completion":467,"start":468,"enrollment":469,"conditions":492,"interventions":493},[87],[471,472],[450,474,475],{"trials":495,"activeCount":96},[],{"intervention":475,"totalTrials":170,"cells":497},{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":502,"PHASE3":504,"PHASE4":506,"NA":512},{"trials":499,"activeCount":96},[],{"trials":501,"activeCount":96},[],{"trials":503,"activeCount":96},[],{"trials":505,"activeCount":96},[],{"trials":507,"activeCount":170,"soonestReadout":466},[508],{"nctId":463,"briefTitle":464,"status":121,"phases":509,"primaryCompletion":466,"completion":467,"start":468,"enrollment":469,"conditions":510,"interventions":511},[87],[471,472],[450,474,475],{"trials":513,"activeCount":96},[],{"intervention":515,"totalTrials":170,"cells":516},"Tau PET scan using MK-6240",{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":521,"PHASE3":523,"PHASE4":538,"NA":540},{"trials":518,"activeCount":96},[],{"trials":520,"activeCount":96},[],{"trials":522,"activeCount":96},[],{"trials":524,"activeCount":170,"soonestReadout":529},[525],{"nctId":526,"briefTitle":527,"status":108,"phases":528,"primaryCompletion":529,"completion":530,"start":531,"enrollment":532,"conditions":533,"interventions":537},"NCT03860857","Biomarker Exploration in Aging, Cognition and Neurodegeneration",[86],"2026-12-22","2027-12-22","2018-05-01",300,[534,535,536],"Alzheimer Disease","Cognitive Impairment","Cognitive Decline",[515],{"trials":539,"activeCount":96},[],{"trials":541,"activeCount":96},[],{"intervention":52,"totalTrials":543,"cells":544},4,{"EARLY_PHASE1":545,"PHASE1":554,"PHASE2":574,"PHASE3":599,"PHASE4":601,"NA":603},{"trials":546,"activeCount":170,"soonestReadout":51},[547],{"nctId":49,"briefTitle":50,"status":121,"phases":548,"primaryCompletion":51,"completion":549,"start":550,"enrollment":9,"conditions":551,"interventions":553},[83],"2026-08","2022-08-03",[552],"Sarcoma, Soft Tissue",[52],{"trials":555,"activeCount":170,"soonestReadout":466},[556],{"nctId":557,"briefTitle":558,"status":108,"phases":559,"primaryCompletion":466,"completion":466,"start":51,"enrollment":560,"conditions":561,"interventions":563},"NCT05733689","Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)",[84],20,[562],"Gastroesophageal Adenocarcinoma",[564,565,566,567,568,569,570,571,572,573],"FLOT","FOLFOX","FOLFIRI","FOLFIRINOX","PACLITAXEL with or without CARBOPLATIN","DOCETAXEL and IRINOTECAN","NIVOLUMAB","PEMBROLIZUMAB","Durvalumab","Trastuzumab",{"trials":575,"activeCount":92,"soonestReadout":41},[576,585],{"nctId":39,"briefTitle":40,"status":121,"phases":577,"primaryCompletion":41,"completion":578,"start":579,"enrollment":580,"conditions":581,"interventions":584},[85],"2026-05-30","2020-02-04",34,[582,583],"Gastric Adenocarcinoma","GastroEsophageal Cancer",[42,52],{"nctId":586,"briefTitle":587,"status":108,"phases":588,"primaryCompletion":589,"completion":282,"start":590,"enrollment":591,"conditions":592,"interventions":597},"NCT06771544","Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma",[85],"2027-12","2024-12-23",14,[593,594,595,596],"Melanoma","Melanoma Stage III","Melanoma (Skin)","Melanoma Stage IV",[52,598],"Cyclophosphamide",{"trials":600,"activeCount":96},[],{"trials":602,"activeCount":96},[],{"trials":604,"activeCount":96},[],{"intervention":67,"totalTrials":606,"cells":607},3,{"EARLY_PHASE1":608,"PHASE1":610,"PHASE2":616,"PHASE3":640,"PHASE4":642,"NA":644},{"trials":609,"activeCount":96},[],{"trials":611,"activeCount":170,"soonestReadout":466},[612],{"nctId":557,"briefTitle":558,"status":108,"phases":613,"primaryCompletion":466,"completion":466,"start":51,"enrollment":560,"conditions":614,"interventions":615},[84],[562],[564,565,566,567,568,569,570,571,572,573],{"trials":617,"activeCount":92,"soonestReadout":66},[618,630],{"nctId":619,"briefTitle":620,"status":108,"phases":621,"primaryCompletion":622,"completion":622,"start":623,"enrollment":624,"conditions":625,"interventions":628},"NCT06682728","Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence",[85],"2026-12-01","2024-11-15",23,[626,627],"Urothelial Carcinoma","Muscle-invasive Bladder Cancer",[629,67],"Sacituzumab Govitecan",{"nctId":64,"briefTitle":65,"status":108,"phases":631,"primaryCompletion":66,"completion":632,"start":633,"enrollment":634,"conditions":635,"interventions":638},[85],"2027-09-01","2020-08-07",35,[636,637],"Hepatocellular Carcinoma","HCC",[67,639,42],"Ipilimumab",{"trials":641,"activeCount":96},[],{"trials":643,"activeCount":96},[],{"trials":645,"activeCount":96},[],{"intervention":573,"totalTrials":543,"cells":647},{"EARLY_PHASE1":648,"PHASE1":650,"PHASE2":656,"PHASE3":701,"PHASE4":703,"NA":705},{"trials":649,"activeCount":96},[],{"trials":651,"activeCount":170,"soonestReadout":466},[652],{"nctId":557,"briefTitle":558,"status":108,"phases":653,"primaryCompletion":466,"completion":466,"start":51,"enrollment":560,"conditions":654,"interventions":655},[84],[562],[564,565,566,567,568,569,570,571,572,573],{"trials":657,"activeCount":170,"soonestReadout":36},[658,668,689],{"nctId":34,"briefTitle":35,"status":121,"phases":659,"primaryCompletion":36,"completion":660,"start":661,"enrollment":113,"conditions":662,"interventions":664},[85],"2036-12","2015-04",[663],"Breast Carcinoma",[37,665,666,573,667],"Paclitaxel","Bevacizumab","Pertuzumab",{"nctId":669,"briefTitle":670,"status":150,"phases":671,"primaryCompletion":672,"completion":672,"start":673,"enrollment":674,"conditions":675,"interventions":685},"NCT00618657","Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting",[85],"2021-07","2008-02",127,[15,676,677,678,679,680,681,682,683,684],"HER2-negative Breast Cancer","HER2-positive Breast Cancer","Recurrent Breast Cancer","Stage IA Breast Cancer","Stage IB Breast Cancer","Stage II Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer",[37,686,687,688],"paclitaxel albumin-stabilized nanoparticle formulation","bevacizumab","trastuzumab",{"nctId":690,"briefTitle":691,"status":150,"phases":692,"primaryCompletion":693,"completion":693,"start":694,"enrollment":695,"conditions":696,"interventions":697},"NCT00254592","Neoadjuvant Treatment of Breast Cancer",[85],"2013-09-04","2005-10",43,[15],[698,598,37,699,700,573,666],"Doxorubicin","Nab-paclitaxel","GM-CSF",{"trials":702,"activeCount":96},[],{"trials":704,"activeCount":96},[],{"trials":706,"activeCount":96},[],{"intervention":598,"totalTrials":606,"cells":708},{"EARLY_PHASE1":709,"PHASE1":711,"PHASE2":731,"PHASE3":741,"PHASE4":743,"NA":745},{"trials":710,"activeCount":96},[],{"trials":712,"activeCount":170,"soonestReadout":75},[713],{"nctId":73,"briefTitle":74,"status":121,"phases":714,"primaryCompletion":75,"completion":75,"start":715,"enrollment":25,"conditions":716,"interventions":728},[84],"2022-07-20",[717,718,719,720,721,722,723,724,725,726,727],"Advanced Lung Non-Small Cell Carcinoma","Metastatic Lung Non-Small Cell Carcinoma","Recurrent Lung Non-Small Cell Carcinoma","Refractory Lung Non-Small Cell Carcinoma","Stage III Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8","Stage IV Lung Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8",[76,729,598,730],"Atezolizumab","Fludarabine",{"trials":732,"activeCount":170,"soonestReadout":589},[733,737],{"nctId":586,"briefTitle":587,"status":108,"phases":734,"primaryCompletion":589,"completion":282,"start":590,"enrollment":591,"conditions":735,"interventions":736},[85],[593,594,595,596],[52,598],{"nctId":690,"briefTitle":691,"status":150,"phases":738,"primaryCompletion":693,"completion":693,"start":694,"enrollment":695,"conditions":739,"interventions":740},[85],[15],[698,598,37,699,700,573,666],{"trials":742,"activeCount":96},[],{"trials":744,"activeCount":96},[],{"trials":746,"activeCount":96},[],{"intervention":42,"totalTrials":606,"cells":748},{"EARLY_PHASE1":749,"PHASE1":751,"PHASE2":766,"PHASE3":776,"PHASE4":778,"NA":780},{"trials":750,"activeCount":96},[],{"trials":752,"activeCount":96},[753],{"nctId":754,"briefTitle":755,"status":150,"phases":756,"primaryCompletion":112,"completion":757,"start":758,"enrollment":759,"conditions":760,"interventions":764},"NCT04868773","Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy",[84],"2024-04-09","2021-07-16",15,[31,761,762,763],"Colorectal Carcinoma","Metastatic Cancer","CRC",[42,765],"TAS-102",{"trials":767,"activeCount":92,"soonestReadout":41},[768,772],{"nctId":39,"briefTitle":40,"status":121,"phases":769,"primaryCompletion":41,"completion":578,"start":579,"enrollment":580,"conditions":770,"interventions":771},[85],[582,583],[42,52],{"nctId":64,"briefTitle":65,"status":108,"phases":773,"primaryCompletion":66,"completion":632,"start":633,"enrollment":634,"conditions":774,"interventions":775},[85],[636,637],[67,639,42],{"trials":777,"activeCount":96},[],{"trials":779,"activeCount":96},[],{"trials":781,"activeCount":96},[],{"intervention":730,"totalTrials":92,"cells":783},{"EARLY_PHASE1":784,"PHASE1":786,"PHASE2":792,"PHASE3":807,"PHASE4":809,"NA":811},{"trials":785,"activeCount":96},[],{"trials":787,"activeCount":170,"soonestReadout":75},[788],{"nctId":73,"briefTitle":74,"status":121,"phases":789,"primaryCompletion":75,"completion":75,"start":715,"enrollment":25,"conditions":790,"interventions":791},[84],[717,718,719,720,721,722,723,724,725,726,727],[76,729,598,730],{"trials":793,"activeCount":170,"soonestReadout":798},[794],{"nctId":795,"briefTitle":796,"status":108,"phases":797,"primaryCompletion":798,"completion":467,"start":799,"enrollment":800,"conditions":801,"interventions":805},"NCT06028828","Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation",[85],"2026-09","2023-09-11",60,[802,803,804],"Allogeneic Hematopoietic Stem Cell Transplantation","Allogeneic Stem Cell Transplantation","Hematologic Malignancies",[730,806],"Melphalan",{"trials":808,"activeCount":96},[],{"trials":810,"activeCount":96},[],{"trials":812,"activeCount":96},[],{"intervention":665,"totalTrials":92,"cells":814},{"EARLY_PHASE1":815,"PHASE1":817,"PHASE2":819,"PHASE3":837,"PHASE4":839,"NA":841},{"trials":816,"activeCount":96},[],{"trials":818,"activeCount":96},[],{"trials":820,"activeCount":92,"soonestReadout":36},[821,825],{"nctId":34,"briefTitle":35,"status":121,"phases":822,"primaryCompletion":36,"completion":660,"start":661,"enrollment":113,"conditions":823,"interventions":824},[85],[663],[37,665,666,573,667],{"nctId":826,"briefTitle":827,"status":121,"phases":828,"primaryCompletion":123,"completion":123,"start":829,"enrollment":165,"conditions":830,"interventions":834},"NCT04762953","Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric\u002FGEJ Peritoneal Carcinomatosis",[85],"2021-02-18",[831,832,833],"Gastric Cancer","Peritoneal Carcinomatosis","Gastroesophageal Junction Adenocarcinoma",[665,665,835,836],"Leucovorin","Fluorouracil",{"trials":838,"activeCount":96},[],{"trials":840,"activeCount":96},[],{"trials":842,"activeCount":96},[],{"intervention":844,"totalTrials":92,"cells":845},"Riluzole",{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":850,"PHASE3":877,"PHASE4":879,"NA":881},{"trials":847,"activeCount":96},[],{"trials":849,"activeCount":96},[],{"trials":851,"activeCount":92,"soonestReadout":123},[852,869],{"nctId":853,"briefTitle":854,"status":108,"phases":855,"primaryCompletion":856,"completion":857,"start":858,"enrollment":859,"conditions":860,"interventions":868},"NCT07447050","Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial",[85],"2027-12-31","2028-12-31","2025-12-23",24,[15,861,862,29,863,31,864,865,866,867],"Sarcoma","Gastric (Stomach) Cancer","Head and Neck Cancer","Ovarian Cancer","Liver Cancer","Genitourinary Cancer","Gynecologic Cancer",[844],{"nctId":870,"briefTitle":871,"status":108,"phases":872,"primaryCompletion":123,"completion":589,"start":873,"enrollment":874,"conditions":875,"interventions":876},"NCT06580002","Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial",[85],"2024-12-02",51,[15,861,831,29,863,31,864,865,866,867],[844],{"trials":878,"activeCount":96},[],{"trials":880,"activeCount":96},[],{"trials":882,"activeCount":96},[],{"intervention":37,"totalTrials":543,"cells":884},{"EARLY_PHASE1":885,"PHASE1":887,"PHASE2":902,"PHASE3":916,"PHASE4":918,"NA":920},{"trials":886,"activeCount":96},[],{"trials":888,"activeCount":96},[889],{"nctId":890,"briefTitle":891,"status":150,"phases":892,"primaryCompletion":893,"completion":893,"start":894,"enrollment":895,"conditions":896,"interventions":900},"NCT02199171","Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer",[84],"2017-10","2014-07",30,[897,898,899],"FIGO Stage IIC-IV Ovarian Carcinoma","Fallopian Tube Carcinoma","Peritoneal Carcinoma",[901],"carboplatin",{"trials":903,"activeCount":170,"soonestReadout":36},[904,908,912],{"nctId":34,"briefTitle":35,"status":121,"phases":905,"primaryCompletion":36,"completion":660,"start":661,"enrollment":113,"conditions":906,"interventions":907},[85],[663],[37,665,666,573,667],{"nctId":669,"briefTitle":670,"status":150,"phases":909,"primaryCompletion":672,"completion":672,"start":673,"enrollment":674,"conditions":910,"interventions":911},[85],[15,676,677,678,679,680,681,682,683,684],[37,686,687,688],{"nctId":690,"briefTitle":691,"status":150,"phases":913,"primaryCompletion":693,"completion":693,"start":694,"enrollment":695,"conditions":914,"interventions":915},[85],[15],[698,598,37,699,700,573,666],{"trials":917,"activeCount":96},[],{"trials":919,"activeCount":96},[],{"trials":921,"activeCount":96},[],{"intervention":666,"totalTrials":606,"cells":923},{"EARLY_PHASE1":924,"PHASE1":926,"PHASE2":928,"PHASE3":942,"PHASE4":944,"NA":946},{"trials":925,"activeCount":96},[],{"trials":927,"activeCount":96},[],{"trials":929,"activeCount":170,"soonestReadout":36},[930,934,938],{"nctId":34,"briefTitle":35,"status":121,"phases":931,"primaryCompletion":36,"completion":660,"start":661,"enrollment":113,"conditions":932,"interventions":933},[85],[663],[37,665,666,573,667],{"nctId":669,"briefTitle":670,"status":150,"phases":935,"primaryCompletion":672,"completion":672,"start":673,"enrollment":674,"conditions":936,"interventions":937},[85],[15,676,677,678,679,680,681,682,683,684],[37,686,687,688],{"nctId":690,"briefTitle":691,"status":150,"phases":939,"primaryCompletion":693,"completion":693,"start":694,"enrollment":695,"conditions":940,"interventions":941},[85],[15],[698,598,37,699,700,573,666],{"trials":943,"activeCount":96},[],{"trials":945,"activeCount":96},[],{"trials":947,"activeCount":96},[],{"intervention":949,"totalTrials":92,"cells":950},"Fulvestrant",{"EARLY_PHASE1":951,"PHASE1":953,"PHASE2":955,"PHASE3":980,"PHASE4":982,"NA":984},{"trials":952,"activeCount":96},[],{"trials":954,"activeCount":96},[],{"trials":956,"activeCount":170,"soonestReadout":857},[957,969],{"nctId":958,"briefTitle":959,"status":108,"phases":960,"primaryCompletion":857,"completion":961,"start":962,"enrollment":560,"conditions":963,"interventions":966},"NCT05524584","Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer",[85],"2031-12-31","2022-08-31",[15,964,965,676],"Metastatic Breast Cancer","Hormone Receptor-positive Breast Cancer",[949,967,968],"Anastrozole","Abemaciclib",{"nctId":970,"briefTitle":971,"status":972,"phases":973,"primaryCompletion":974,"completion":974,"start":975,"enrollment":170,"conditions":976,"interventions":979},"NCT04305236","Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER\u002FPR +HER Negative Breast Cancer","TERMINATED",[85],"2022-02-16","2020-07-23",[977,978],"Breast Neoplasm","Hormone Receptor Positive Breast Carcinoma",[968,949],{"trials":981,"activeCount":96},[],{"trials":983,"activeCount":96},[],{"trials":985,"activeCount":96},[],{"intervention":968,"totalTrials":92,"cells":987},{"EARLY_PHASE1":988,"PHASE1":990,"PHASE2":992,"PHASE3":1002,"PHASE4":1004,"NA":1006},{"trials":989,"activeCount":96},[],{"trials":991,"activeCount":96},[],{"trials":993,"activeCount":170,"soonestReadout":857},[994,998],{"nctId":958,"briefTitle":959,"status":108,"phases":995,"primaryCompletion":857,"completion":961,"start":962,"enrollment":560,"conditions":996,"interventions":997},[85],[15,964,965,676],[949,967,968],{"nctId":970,"briefTitle":971,"status":972,"phases":999,"primaryCompletion":974,"completion":974,"start":975,"enrollment":170,"conditions":1000,"interventions":1001},[85],[977,978],[968,949],{"trials":1003,"activeCount":96},[],{"trials":1005,"activeCount":96},[],{"trials":1007,"activeCount":96},[],{"intervention":1009,"totalTrials":170,"cells":1010},"Caffeine",{"EARLY_PHASE1":1011,"PHASE1":1013,"PHASE2":1015,"PHASE3":1025,"PHASE4":1027,"NA":1029},{"trials":1012,"activeCount":96},[],{"trials":1014,"activeCount":96},[],{"trials":1016,"activeCount":170,"soonestReadout":123},[1017],{"nctId":1018,"briefTitle":1019,"status":121,"phases":1020,"primaryCompletion":123,"completion":190,"start":1021,"enrollment":443,"conditions":1022,"interventions":1024},"NCT06327152","Caffeine Use in the Management of Preterm Infants",[85],"2024-02-22",[1023],"Apnea of Prematurity",[1009],{"trials":1026,"activeCount":96},[],{"trials":1028,"activeCount":96},[],{"trials":1030,"activeCount":96},[],{"intervention":1032,"totalTrials":170,"cells":1033},"N-Acetylcysteine",{"EARLY_PHASE1":1034,"PHASE1":1036,"PHASE2":1038,"PHASE3":1054,"PHASE4":1056,"NA":1058},{"trials":1035,"activeCount":96},[],{"trials":1037,"activeCount":96},[],{"trials":1039,"activeCount":170,"soonestReadout":1044},[1040],{"nctId":1041,"briefTitle":1042,"status":108,"phases":1043,"primaryCompletion":1044,"completion":1044,"start":1045,"enrollment":1046,"conditions":1047,"interventions":1053},"NCT05123365","An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms",[84,85],"2026-11-15","2022-01-03",27,[1048,1049,1050,1051,1052],"Myeloproliferative Neoplasm","MPN","Essential Thrombocythemia","Polycythemia Vera","Myelofibrosis",[1032],{"trials":1055,"activeCount":96},[],{"trials":1057,"activeCount":96},[],{"trials":1059,"activeCount":96},[],{"intervention":1061,"totalTrials":170,"cells":1062},"AHCC®capsules",{"EARLY_PHASE1":1063,"PHASE1":1065,"PHASE2":1067,"PHASE3":1078,"PHASE4":1080,"NA":1082},{"trials":1064,"activeCount":96},[],{"trials":1066,"activeCount":96},[],{"trials":1068,"activeCount":170,"soonestReadout":589},[1069],{"nctId":1070,"briefTitle":1071,"status":108,"phases":1072,"primaryCompletion":589,"completion":589,"start":1073,"enrollment":580,"conditions":1074,"interventions":1077},"NCT06693323","Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W\u002F SOC Tx for HPV+ Pts W\u002F HNSCC",[85],"2024-12-04",[1075,1076],"HNSCC","Head and Neck Squamous Cell Carcinoma",[1061],{"trials":1079,"activeCount":96},[],{"trials":1081,"activeCount":96},[],{"trials":1083,"activeCount":96},[],{"intervention":806,"totalTrials":170,"cells":1085},{"EARLY_PHASE1":1086,"PHASE1":1088,"PHASE2":1090,"PHASE3":1096,"PHASE4":1098,"NA":1100},{"trials":1087,"activeCount":96},[],{"trials":1089,"activeCount":96},[],{"trials":1091,"activeCount":170,"soonestReadout":798},[1092],{"nctId":795,"briefTitle":796,"status":108,"phases":1093,"primaryCompletion":798,"completion":467,"start":799,"enrollment":800,"conditions":1094,"interventions":1095},[85],[802,803,804],[730,806],{"trials":1097,"activeCount":96},[],{"trials":1099,"activeCount":96},[],{"trials":1101,"activeCount":96},[],{"intervention":1103,"totalTrials":170,"cells":1104},"Letermovir",{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1109,"PHASE3":1122,"PHASE4":1124,"NA":1126},{"trials":1106,"activeCount":96},[],{"trials":1108,"activeCount":96},[],{"trials":1110,"activeCount":170,"soonestReadout":1115},[1111],{"nctId":1112,"briefTitle":1113,"status":108,"phases":1114,"primaryCompletion":1115,"completion":1116,"start":1117,"enrollment":1118,"conditions":1119,"interventions":1121},"NCT06453460","CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT",[85],"2028-06","2029-06","2024-06-27",50,[1120,803],"CMV",[1103],{"trials":1123,"activeCount":96},[],{"trials":1125,"activeCount":96},[],{"trials":1127,"activeCount":96},[],{"intervention":667,"totalTrials":170,"cells":1129},{"EARLY_PHASE1":1130,"PHASE1":1132,"PHASE2":1134,"PHASE3":1140,"PHASE4":1142,"NA":1144},{"trials":1131,"activeCount":96},[],{"trials":1133,"activeCount":96},[],{"trials":1135,"activeCount":170,"soonestReadout":36},[1136],{"nctId":34,"briefTitle":35,"status":121,"phases":1137,"primaryCompletion":36,"completion":660,"start":661,"enrollment":113,"conditions":1138,"interventions":1139},[85],[663],[37,665,666,573,667],{"trials":1141,"activeCount":96},[],{"trials":1143,"activeCount":96},[],{"trials":1145,"activeCount":96},[],{"intervention":967,"totalTrials":170,"cells":1147},{"EARLY_PHASE1":1148,"PHASE1":1150,"PHASE2":1152,"PHASE3":1158,"PHASE4":1160,"NA":1162},{"trials":1149,"activeCount":96},[],{"trials":1151,"activeCount":96},[],{"trials":1153,"activeCount":170,"soonestReadout":857},[1154],{"nctId":958,"briefTitle":959,"status":108,"phases":1155,"primaryCompletion":857,"completion":961,"start":962,"enrollment":560,"conditions":1156,"interventions":1157},[85],[15,964,965,676],[949,967,968],{"trials":1159,"activeCount":96},[],{"trials":1161,"activeCount":96},[],{"trials":1163,"activeCount":96},[],{"intervention":1165,"totalTrials":170,"cells":1166},"Mirtazapine",{"EARLY_PHASE1":1167,"PHASE1":1169,"PHASE2":1171,"PHASE3":1182,"PHASE4":1184,"NA":1186},{"trials":1168,"activeCount":96},[],{"trials":1170,"activeCount":96},[],{"trials":1172,"activeCount":170,"soonestReadout":1177},[1173],{"nctId":1174,"briefTitle":1175,"status":121,"phases":1176,"primaryCompletion":1177,"completion":1177,"start":1178,"enrollment":113,"conditions":1179,"interventions":1181},"NCT03935685","Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ",[85],"2030-12-31","2019-02-26",[1180],"Glioma of Brain",[1165],{"trials":1183,"activeCount":96},[],{"trials":1185,"activeCount":96},[],{"trials":1187,"activeCount":96},[],{"intervention":1189,"totalTrials":170,"cells":1190},"Fianlimab",{"EARLY_PHASE1":1191,"PHASE1":1193,"PHASE2":1195,"PHASE3":1207,"PHASE4":1209,"NA":1211},{"trials":1192,"activeCount":96},[],{"trials":1194,"activeCount":96},[],{"trials":1196,"activeCount":170,"soonestReadout":1201},[1197],{"nctId":1198,"briefTitle":1199,"status":215,"phases":1200,"primaryCompletion":1201,"completion":1202,"start":1203,"enrollment":634,"conditions":1204,"interventions":1205},"NCT07527325","Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma",[85],"2029-02-01","2030-02-01","2026-04-30",[595],[1189,1206],"Cemiplimab",{"trials":1208,"activeCount":96},[],{"trials":1210,"activeCount":96},[],{"trials":1212,"activeCount":96},[],{"intervention":1206,"totalTrials":170,"cells":1214},{"EARLY_PHASE1":1215,"PHASE1":1217,"PHASE2":1219,"PHASE3":1225,"PHASE4":1227,"NA":1229},{"trials":1216,"activeCount":96},[],{"trials":1218,"activeCount":96},[],{"trials":1220,"activeCount":170,"soonestReadout":1201},[1221],{"nctId":1198,"briefTitle":1199,"status":215,"phases":1222,"primaryCompletion":1201,"completion":1202,"start":1203,"enrollment":634,"conditions":1223,"interventions":1224},[85],[595],[1189,1206],{"trials":1226,"activeCount":96},[],{"trials":1228,"activeCount":96},[],{"trials":1230,"activeCount":96},[],{"intervention":629,"totalTrials":170,"cells":1232},{"EARLY_PHASE1":1233,"PHASE1":1235,"PHASE2":1237,"PHASE3":1243,"PHASE4":1245,"NA":1247},{"trials":1234,"activeCount":96},[],{"trials":1236,"activeCount":96},[],{"trials":1238,"activeCount":170,"soonestReadout":622},[1239],{"nctId":619,"briefTitle":620,"status":108,"phases":1240,"primaryCompletion":622,"completion":622,"start":623,"enrollment":624,"conditions":1241,"interventions":1242},[85],[626,627],[629,67],{"trials":1244,"activeCount":96},[],{"trials":1246,"activeCount":96},[],{"trials":1248,"activeCount":96},[],{"intervention":1250,"totalTrials":170,"cells":1251},"Spedox-6",{"EARLY_PHASE1":1252,"PHASE1":1254,"PHASE2":1256,"PHASE3":1273,"PHASE4":1275,"NA":1277},{"trials":1253,"activeCount":96},[],{"trials":1255,"activeCount":96},[],{"trials":1257,"activeCount":170,"soonestReadout":1262},[1258],{"nctId":1259,"briefTitle":1260,"status":108,"phases":1261,"primaryCompletion":1262,"completion":961,"start":1263,"enrollment":1264,"conditions":1265,"interventions":1270},"NCT07064018","Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies",[84,85],"2029-12-31","2025-04-30",67,[1266,1267,1268,24,864,1269],"Soft-tissue Sarcoma","Triple Negative Breast Cancer","Non-small Cell Lung Cancer","KRAS Mutation-Related Tumors",[1250,1271,1272],"Pegfilgrastim","Filgrastim",{"trials":1274,"activeCount":96},[],{"trials":1276,"activeCount":96},[],{"trials":1278,"activeCount":96},[],{"intervention":1271,"totalTrials":170,"cells":1280},{"EARLY_PHASE1":1281,"PHASE1":1283,"PHASE2":1285,"PHASE3":1291,"PHASE4":1293,"NA":1295},{"trials":1282,"activeCount":96},[],{"trials":1284,"activeCount":96},[],{"trials":1286,"activeCount":170,"soonestReadout":1262},[1287],{"nctId":1259,"briefTitle":1260,"status":108,"phases":1288,"primaryCompletion":1262,"completion":961,"start":1263,"enrollment":1264,"conditions":1289,"interventions":1290},[84,85],[1266,1267,1268,24,864,1269],[1250,1271,1272],{"trials":1292,"activeCount":96},[],{"trials":1294,"activeCount":96},[],{"trials":1296,"activeCount":96},[],{"intervention":1272,"totalTrials":170,"cells":1298},{"EARLY_PHASE1":1299,"PHASE1":1301,"PHASE2":1303,"PHASE3":1309,"PHASE4":1311,"NA":1313},{"trials":1300,"activeCount":96},[],{"trials":1302,"activeCount":96},[],{"trials":1304,"activeCount":170,"soonestReadout":1262},[1305],{"nctId":1259,"briefTitle":1260,"status":108,"phases":1306,"primaryCompletion":1262,"completion":961,"start":1263,"enrollment":1264,"conditions":1307,"interventions":1308},[84,85],[1266,1267,1268,24,864,1269],[1250,1271,1272],{"trials":1310,"activeCount":96},[],{"trials":1312,"activeCount":96},[],{"trials":1314,"activeCount":96},[],{"intervention":1316,"totalTrials":170,"cells":1317},"N-Acetyl-Cysteine",{"EARLY_PHASE1":1318,"PHASE1":1320,"PHASE2":1322,"PHASE3":1332,"PHASE4":1334,"NA":1336},{"trials":1319,"activeCount":96},[],{"trials":1321,"activeCount":96},[],{"trials":1323,"activeCount":170,"soonestReadout":123},[1324],{"nctId":1325,"briefTitle":1326,"status":215,"phases":1327,"primaryCompletion":123,"completion":589,"start":1328,"enrollment":1329,"conditions":1330,"interventions":1331},"NCT04520139","Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W\u002F PBT",[84,85],"2026-05",102,[864,535],[1316],{"trials":1333,"activeCount":96},[],{"trials":1335,"activeCount":96},[],{"trials":1337,"activeCount":96},[],{"intervention":47,"totalTrials":170,"cells":1339},{"EARLY_PHASE1":1340,"PHASE1":1342,"PHASE2":1344,"PHASE3":1355,"PHASE4":1357,"NA":1359},{"trials":1341,"activeCount":96},[],{"trials":1343,"activeCount":96},[],{"trials":1345,"activeCount":170,"soonestReadout":46},[1346],{"nctId":44,"briefTitle":45,"status":121,"phases":1347,"primaryCompletion":46,"completion":1348,"start":1349,"enrollment":895,"conditions":1350,"interventions":1353},[85],"2027-06-30","2020-02-19",[1351,1352],"Acute Myelogenous Leukemia (AML) Due to Therapy","Acute Myeloid Leukemia With Myelodysplasia-Related Changes",[47,1354],"CPX-351",{"trials":1356,"activeCount":96},[],{"trials":1358,"activeCount":96},[],{"trials":1360,"activeCount":96},[],{"intervention":1354,"totalTrials":170,"cells":1362},{"EARLY_PHASE1":1363,"PHASE1":1365,"PHASE2":1367,"PHASE3":1373,"PHASE4":1375,"NA":1377},{"trials":1364,"activeCount":96},[],{"trials":1366,"activeCount":96},[],{"trials":1368,"activeCount":170,"soonestReadout":46},[1369],{"nctId":44,"briefTitle":45,"status":121,"phases":1370,"primaryCompletion":46,"completion":1348,"start":1349,"enrollment":895,"conditions":1371,"interventions":1372},[85],[1351,1352],[47,1354],{"trials":1374,"activeCount":96},[],{"trials":1376,"activeCount":96},[],{"trials":1378,"activeCount":96},[],{"intervention":639,"totalTrials":170,"cells":1380},{"EARLY_PHASE1":1381,"PHASE1":1383,"PHASE2":1385,"PHASE3":1391,"PHASE4":1393,"NA":1395},{"trials":1382,"activeCount":96},[],{"trials":1384,"activeCount":96},[],{"trials":1386,"activeCount":170,"soonestReadout":66},[1387],{"nctId":64,"briefTitle":65,"status":108,"phases":1388,"primaryCompletion":66,"completion":632,"start":633,"enrollment":634,"conditions":1389,"interventions":1390},[85],[636,637],[67,639,42],{"trials":1392,"activeCount":96},[],{"trials":1394,"activeCount":96},[],{"trials":1396,"activeCount":96},[],{"intervention":835,"totalTrials":170,"cells":1398},{"EARLY_PHASE1":1399,"PHASE1":1401,"PHASE2":1403,"PHASE3":1409,"PHASE4":1411,"NA":1413},{"trials":1400,"activeCount":96},[],{"trials":1402,"activeCount":96},[],{"trials":1404,"activeCount":170,"soonestReadout":123},[1405],{"nctId":826,"briefTitle":827,"status":121,"phases":1406,"primaryCompletion":123,"completion":123,"start":829,"enrollment":165,"conditions":1407,"interventions":1408},[85],[831,832,833],[665,665,835,836],{"trials":1410,"activeCount":96},[],{"trials":1412,"activeCount":96},[],{"trials":1414,"activeCount":96},[],{"intervention":836,"totalTrials":170,"cells":1416},{"EARLY_PHASE1":1417,"PHASE1":1419,"PHASE2":1421,"PHASE3":1427,"PHASE4":1429,"NA":1431},{"trials":1418,"activeCount":96},[],{"trials":1420,"activeCount":96},[],{"trials":1422,"activeCount":170,"soonestReadout":123},[1423],{"nctId":826,"briefTitle":827,"status":121,"phases":1424,"primaryCompletion":123,"completion":123,"start":829,"enrollment":165,"conditions":1425,"interventions":1426},[85],[831,832,833],[665,665,835,836],{"trials":1428,"activeCount":96},[],{"trials":1430,"activeCount":96},[],{"trials":1432,"activeCount":96},[],{"intervention":62,"totalTrials":170,"cells":1434},{"EARLY_PHASE1":1435,"PHASE1":1437,"PHASE2":1439,"PHASE3":1448,"PHASE4":1450,"NA":1452},{"trials":1436,"activeCount":96},[],{"trials":1438,"activeCount":96},[],{"trials":1440,"activeCount":170,"soonestReadout":61},[1441],{"nctId":59,"briefTitle":60,"status":108,"phases":1442,"primaryCompletion":61,"completion":466,"start":1443,"enrollment":1444,"conditions":1445,"interventions":1447},[84,85],"2025-09-16",10,[1052,1446],"Myelofibrosis; Anemia",[62],{"trials":1449,"activeCount":96},[],{"trials":1451,"activeCount":96},[],{"trials":1453,"activeCount":96},[],{"intervention":572,"totalTrials":92,"cells":1455},{"EARLY_PHASE1":1456,"PHASE1":1471,"PHASE2":1477,"PHASE3":1479,"PHASE4":1481,"NA":1483},{"trials":1457,"activeCount":170,"soonestReadout":281},[1458],{"nctId":1459,"briefTitle":1460,"status":215,"phases":1461,"primaryCompletion":281,"completion":1462,"start":1463,"enrollment":580,"conditions":1464,"interventions":1469},"NCT06824363","ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w\u002FARID1a Mu",[83],"2028-07","2026-04",[1465,1466,1467,1468],"Solid Tumor, Adult","Malignant Solid Tumor","Stomach Adenocarcinoma","Esophageal Adenocarcinoma",[1470,572],"Tremelimumab",{"trials":1472,"activeCount":170,"soonestReadout":466},[1473],{"nctId":557,"briefTitle":558,"status":108,"phases":1474,"primaryCompletion":466,"completion":466,"start":51,"enrollment":560,"conditions":1475,"interventions":1476},[84],[562],[564,565,566,567,568,569,570,571,572,573],{"trials":1478,"activeCount":96},[],{"trials":1480,"activeCount":96},[],{"trials":1482,"activeCount":96},[],{"trials":1484,"activeCount":96},[],{"intervention":1486,"totalTrials":606,"cells":1487},"Irinotecan",{"EARLY_PHASE1":1488,"PHASE1":1490,"PHASE2":1513,"PHASE3":1526,"PHASE4":1528,"NA":1530},{"trials":1489,"activeCount":96},[],{"trials":1491,"activeCount":170,"soonestReadout":1496},[1492,1504],{"nctId":1493,"briefTitle":1494,"status":108,"phases":1495,"primaryCompletion":1496,"completion":1497,"start":1498,"enrollment":1499,"conditions":1500,"interventions":1502},"NCT04920032","Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas",[84],"2027-01-21","2028-01-21","2021-08-26",22,[1501,31],"Colon Adenocarcinoma",[765,1486,1503],"Standard Treatment",{"nctId":1505,"briefTitle":1506,"status":150,"phases":1507,"primaryCompletion":1508,"completion":1509,"start":1510,"enrollment":560,"conditions":1511,"interventions":1512},"NCT04074343","TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma",[84],"2021-07-14","2022-07-21","2019-08-26",[582,583],[765,1486],{"trials":1514,"activeCount":96},[1515],{"nctId":1516,"briefTitle":1517,"status":972,"phases":1518,"primaryCompletion":1519,"completion":1519,"start":1520,"enrollment":543,"conditions":1521,"interventions":1524},"NCT00256269","Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma",[85],"2007-02-07","2005-06",[1522,1523],"Esophageal Cancer","Gastroesophageal Cancer",[1525,1486],"Oxaliplatin",{"trials":1527,"activeCount":96},[],{"trials":1529,"activeCount":96},[],{"trials":1531,"activeCount":96},[],{"intervention":765,"totalTrials":606,"cells":1533},{"EARLY_PHASE1":1534,"PHASE1":1536,"PHASE2":1550,"PHASE3":1552,"PHASE4":1554,"NA":1556},{"trials":1535,"activeCount":96},[],{"trials":1537,"activeCount":170,"soonestReadout":1496},[1538,1542,1546],{"nctId":1493,"briefTitle":1494,"status":108,"phases":1539,"primaryCompletion":1496,"completion":1497,"start":1498,"enrollment":1499,"conditions":1540,"interventions":1541},[84],[1501,31],[765,1486,1503],{"nctId":754,"briefTitle":755,"status":150,"phases":1543,"primaryCompletion":112,"completion":757,"start":758,"enrollment":759,"conditions":1544,"interventions":1545},[84],[31,761,762,763],[42,765],{"nctId":1505,"briefTitle":1506,"status":150,"phases":1547,"primaryCompletion":1508,"completion":1509,"start":1510,"enrollment":560,"conditions":1548,"interventions":1549},[84],[582,583],[765,1486],{"trials":1551,"activeCount":96},[],{"trials":1553,"activeCount":96},[],{"trials":1555,"activeCount":96},[],{"trials":1557,"activeCount":96},[],{"intervention":1559,"totalTrials":92,"cells":1560},"Pitavastatin",{"EARLY_PHASE1":1561,"PHASE1":1563,"PHASE2":1593,"PHASE3":1595,"PHASE4":1597,"NA":1599},{"trials":1562,"activeCount":96},[],{"trials":1564,"activeCount":170,"soonestReadout":1585},[1565,1581],{"nctId":1566,"briefTitle":1567,"status":150,"phases":1568,"primaryCompletion":1569,"completion":1570,"start":1571,"enrollment":25,"conditions":1572,"interventions":1579},"NCT04512105","Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia",[84],"2024-07-20","2025-02-05","2020-12-02",[1573,1574,1575,1576,1577,1578],"Acute Myeloid Leukemia","Chronic Lymphocytic Leukemia","AML, Adult","CLL","CLL, Relapsed","CLL, Refractory",[1559,1580],"Venetoclax",{"nctId":1582,"briefTitle":1583,"status":108,"phases":1584,"primaryCompletion":1585,"completion":1586,"start":1587,"enrollment":1588,"conditions":1589,"interventions":1592},"NCT07549958","PhIbRandomGemcitabine(G)w\u002For w\u002FOut Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)",[84],"2027-03-31","2028-03-31","2026-03-24",18,[1590,1591],"Pancreatic Cancer","Pancreatic Cancer Metastatic",[1559],{"trials":1594,"activeCount":96},[],{"trials":1596,"activeCount":96},[],{"trials":1598,"activeCount":96},[],{"trials":1600,"activeCount":96},[],{"intervention":76,"totalTrials":170,"cells":1602},{"EARLY_PHASE1":1603,"PHASE1":1605,"PHASE2":1611,"PHASE3":1613,"PHASE4":1615,"NA":1617},{"trials":1604,"activeCount":96},[],{"trials":1606,"activeCount":170,"soonestReadout":75},[1607],{"nctId":73,"briefTitle":74,"status":121,"phases":1608,"primaryCompletion":75,"completion":75,"start":715,"enrollment":25,"conditions":1609,"interventions":1610},[84],[717,718,719,720,721,722,723,724,725,726,727],[76,729,598,730],{"trials":1612,"activeCount":96},[],{"trials":1614,"activeCount":96},[],{"trials":1616,"activeCount":96},[],{"trials":1618,"activeCount":96},[],{"intervention":729,"totalTrials":170,"cells":1620},{"EARLY_PHASE1":1621,"PHASE1":1623,"PHASE2":1629,"PHASE3":1631,"PHASE4":1633,"NA":1635},{"trials":1622,"activeCount":96},[],{"trials":1624,"activeCount":170,"soonestReadout":75},[1625],{"nctId":73,"briefTitle":74,"status":121,"phases":1626,"primaryCompletion":75,"completion":75,"start":715,"enrollment":25,"conditions":1627,"interventions":1628},[84],[717,718,719,720,721,722,723,724,725,726,727],[76,729,598,730],{"trials":1630,"activeCount":96},[],{"trials":1632,"activeCount":96},[],{"trials":1634,"activeCount":96},[],{"trials":1636,"activeCount":96},[],{"intervention":1503,"totalTrials":170,"cells":1638},{"EARLY_PHASE1":1639,"PHASE1":1641,"PHASE2":1647,"PHASE3":1649,"PHASE4":1651,"NA":1653},{"trials":1640,"activeCount":96},[],{"trials":1642,"activeCount":170,"soonestReadout":1496},[1643],{"nctId":1493,"briefTitle":1494,"status":108,"phases":1644,"primaryCompletion":1496,"completion":1497,"start":1498,"enrollment":1499,"conditions":1645,"interventions":1646},[84],[1501,31],[765,1486,1503],{"trials":1648,"activeCount":96},[],{"trials":1650,"activeCount":96},[],{"trials":1652,"activeCount":96},[],{"trials":1654,"activeCount":96},[],{"intervention":564,"totalTrials":170,"cells":1656},{"EARLY_PHASE1":1657,"PHASE1":1659,"PHASE2":1665,"PHASE3":1667,"PHASE4":1669,"NA":1671},{"trials":1658,"activeCount":96},[],{"trials":1660,"activeCount":170,"soonestReadout":466},[1661],{"nctId":557,"briefTitle":558,"status":108,"phases":1662,"primaryCompletion":466,"completion":466,"start":51,"enrollment":560,"conditions":1663,"interventions":1664},[84],[562],[564,565,566,567,568,569,570,571,572,573],{"trials":1666,"activeCount":96},[],{"trials":1668,"activeCount":96},[],{"trials":1670,"activeCount":96},[],{"trials":1672,"activeCount":96},[],{"intervention":565,"totalTrials":170,"cells":1674},{"EARLY_PHASE1":1675,"PHASE1":1677,"PHASE2":1683,"PHASE3":1685,"PHASE4":1687,"NA":1689},{"trials":1676,"activeCount":96},[],{"trials":1678,"activeCount":170,"soonestReadout":466},[1679],{"nctId":557,"briefTitle":558,"status":108,"phases":1680,"primaryCompletion":466,"completion":466,"start":51,"enrollment":560,"conditions":1681,"interventions":1682},[84],[562],[564,565,566,567,568,569,570,571,572,573],{"trials":1684,"activeCount":96},[],{"trials":1686,"activeCount":96},[],{"trials":1688,"activeCount":96},[],{"trials":1690,"activeCount":96},[],{"intervention":566,"totalTrials":170,"cells":1692},{"EARLY_PHASE1":1693,"PHASE1":1695,"PHASE2":1701,"PHASE3":1703,"PHASE4":1705,"NA":1707},{"trials":1694,"activeCount":96},[],{"trials":1696,"activeCount":170,"soonestReadout":466},[1697],{"nctId":557,"briefTitle":558,"status":108,"phases":1698,"primaryCompletion":466,"completion":466,"start":51,"enrollment":560,"conditions":1699,"interventions":1700},[84],[562],[564,565,566,567,568,569,570,571,572,573],{"trials":1702,"activeCount":96},[],{"trials":1704,"activeCount":96},[],{"trials":1706,"activeCount":96},[],{"trials":1708,"activeCount":96},[],{"intervention":567,"totalTrials":170,"cells":1710},{"EARLY_PHASE1":1711,"PHASE1":1713,"PHASE2":1719,"PHASE3":1721,"PHASE4":1723,"NA":1725},{"trials":1712,"activeCount":96},[],{"trials":1714,"activeCount":170,"soonestReadout":466},[1715],{"nctId":557,"briefTitle":558,"status":108,"phases":1716,"primaryCompletion":466,"completion":466,"start":51,"enrollment":560,"conditions":1717,"interventions":1718},[84],[562],[564,565,566,567,568,569,570,571,572,573],{"trials":1720,"activeCount":96},[],{"trials":1722,"activeCount":96},[],{"trials":1724,"activeCount":96},[],{"trials":1726,"activeCount":96},[],{"intervention":568,"totalTrials":170,"cells":1728},{"EARLY_PHASE1":1729,"PHASE1":1731,"PHASE2":1737,"PHASE3":1739,"PHASE4":1741,"NA":1743},{"trials":1730,"activeCount":96},[],{"trials":1732,"activeCount":170,"soonestReadout":466},[1733],{"nctId":557,"briefTitle":558,"status":108,"phases":1734,"primaryCompletion":466,"completion":466,"start":51,"enrollment":560,"conditions":1735,"interventions":1736},[84],[562],[564,565,566,567,568,569,570,571,572,573],{"trials":1738,"activeCount":96},[],{"trials":1740,"activeCount":96},[],{"trials":1742,"activeCount":96},[],{"trials":1744,"activeCount":96},[],{"intervention":569,"totalTrials":170,"cells":1746},{"EARLY_PHASE1":1747,"PHASE1":1749,"PHASE2":1755,"PHASE3":1757,"PHASE4":1759,"NA":1761},{"trials":1748,"activeCount":96},[],{"trials":1750,"activeCount":170,"soonestReadout":466},[1751],{"nctId":557,"briefTitle":558,"status":108,"phases":1752,"primaryCompletion":466,"completion":466,"start":51,"enrollment":560,"conditions":1753,"interventions":1754},[84],[562],[564,565,566,567,568,569,570,571,572,573],{"trials":1756,"activeCount":96},[],{"trials":1758,"activeCount":96},[],{"trials":1760,"activeCount":96},[],{"trials":1762,"activeCount":96},[],{"intervention":1764,"totalTrials":170,"cells":1765},"Potassium citrate",{"EARLY_PHASE1":1766,"PHASE1":1768,"PHASE2":1779,"PHASE3":1781,"PHASE4":1783,"NA":1785},{"trials":1767,"activeCount":96},[],{"trials":1769,"activeCount":170,"soonestReadout":80},[1770],{"nctId":1771,"briefTitle":1772,"status":108,"phases":1773,"primaryCompletion":80,"completion":80,"start":1774,"enrollment":125,"conditions":1775,"interventions":1777},"NCT06335537","Impact of Sodium Bicarbonate on 24-hour Urine Parameters in Hypocitriuric and Uric Acid Stone Formers",[84],"2025-05-01",[1776],"Uric Acid Stones",[1764,1778],"Sodium bicarbonate",{"trials":1780,"activeCount":96},[],{"trials":1782,"activeCount":96},[],{"trials":1784,"activeCount":96},[],{"trials":1786,"activeCount":96},[],{"intervention":1778,"totalTrials":170,"cells":1788},{"EARLY_PHASE1":1789,"PHASE1":1791,"PHASE2":1797,"PHASE3":1799,"PHASE4":1801,"NA":1803},{"trials":1790,"activeCount":96},[],{"trials":1792,"activeCount":170,"soonestReadout":80},[1793],{"nctId":1771,"briefTitle":1772,"status":108,"phases":1794,"primaryCompletion":80,"completion":80,"start":1774,"enrollment":125,"conditions":1795,"interventions":1796},[84],[1776],[1764,1778],{"trials":1798,"activeCount":96},[],{"trials":1800,"activeCount":96},[],{"trials":1802,"activeCount":96},[],{"trials":1804,"activeCount":96},[],{"intervention":1806,"totalTrials":170,"cells":1807},"Pafolacianine (CYTALUX) with intraoperative fluorescent near-infrared (NIR) imaging",{"EARLY_PHASE1":1808,"PHASE1":1820,"PHASE2":1822,"PHASE3":1824,"PHASE4":1826,"NA":1828},{"trials":1809,"activeCount":170,"soonestReadout":1814},[1810],{"nctId":1811,"briefTitle":1812,"status":108,"phases":1813,"primaryCompletion":1814,"completion":1815,"start":1816,"enrollment":1444,"conditions":1817,"interventions":1819},"NCT06511037","PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis",[83],"2026-11-30","2027-11-30","2024-11-13",[1818,832],"Gastrointestinal Cancer",[1806],{"trials":1821,"activeCount":96},[],{"trials":1823,"activeCount":96},[],{"trials":1825,"activeCount":96},[],{"trials":1827,"activeCount":96},[],{"trials":1829,"activeCount":96},[],{"intervention":1831,"totalTrials":170,"cells":1832},"ICG",{"EARLY_PHASE1":1833,"PHASE1":1845,"PHASE2":1847,"PHASE3":1849,"PHASE4":1851,"NA":1853},{"trials":1834,"activeCount":170,"soonestReadout":1462},[1835],{"nctId":1836,"briefTitle":1837,"status":108,"phases":1838,"primaryCompletion":1462,"completion":1839,"start":1840,"enrollment":1841,"conditions":1842,"interventions":1844},"NCT06446648","Impact of Intraoperative ICG on Functional Outc in RARP",[83],"2030-07","2024-07-12",400,[1843],"Prostate Adenocarcinoma",[1831],{"trials":1846,"activeCount":96},[],{"trials":1848,"activeCount":96},[],{"trials":1850,"activeCount":96},[],{"trials":1852,"activeCount":96},[],{"trials":1854,"activeCount":96},[],{"intervention":1470,"totalTrials":170,"cells":1856},{"EARLY_PHASE1":1857,"PHASE1":1863,"PHASE2":1865,"PHASE3":1867,"PHASE4":1869,"NA":1871},{"trials":1858,"activeCount":170,"soonestReadout":281},[1859],{"nctId":1459,"briefTitle":1460,"status":215,"phases":1860,"primaryCompletion":281,"completion":1462,"start":1463,"enrollment":580,"conditions":1861,"interventions":1862},[83],[1465,1466,1467,1468],[1470,572],{"trials":1864,"activeCount":96},[],{"trials":1866,"activeCount":96},[],{"trials":1868,"activeCount":96},[],{"trials":1870,"activeCount":96},[],{"trials":1872,"activeCount":96},[],{"intervention":71,"totalTrials":170,"cells":1874},{"EARLY_PHASE1":1875,"PHASE1":1886,"PHASE2":1888,"PHASE3":1890,"PHASE4":1892,"NA":1894},{"trials":1876,"activeCount":170,"soonestReadout":66},[1877],{"nctId":69,"briefTitle":70,"status":108,"phases":1878,"primaryCompletion":66,"completion":1879,"start":1880,"enrollment":165,"conditions":1881,"interventions":1884},[83],"2027-06-01","2021-10-09",[1882,1883],"Open Wound","Wound Heal",[71,1885],"Micro\u002Fnanobubble",{"trials":1887,"activeCount":96},[],{"trials":1889,"activeCount":96},[],{"trials":1891,"activeCount":96},[],{"trials":1893,"activeCount":96},[],{"trials":1895,"activeCount":96},[],{"intervention":1885,"totalTrials":170,"cells":1897},{"EARLY_PHASE1":1898,"PHASE1":1904,"PHASE2":1906,"PHASE3":1908,"PHASE4":1910,"NA":1912},{"trials":1899,"activeCount":170,"soonestReadout":66},[1900],{"nctId":69,"briefTitle":70,"status":108,"phases":1901,"primaryCompletion":66,"completion":1879,"start":1880,"enrollment":165,"conditions":1902,"interventions":1903},[83],[1882,1883],[71,1885],{"trials":1905,"activeCount":96},[],{"trials":1907,"activeCount":96},[],{"trials":1909,"activeCount":96},[],{"trials":1911,"activeCount":96},[],{"trials":1913,"activeCount":96},[],{"intervention":57,"totalTrials":92,"cells":1915},{"EARLY_PHASE1":1916,"PHASE1":1918,"PHASE2":1920,"PHASE3":1922,"PHASE4":1924,"NA":1926},{"trials":1917,"activeCount":96},[],{"trials":1919,"activeCount":96},[],{"trials":1921,"activeCount":96},[],{"trials":1923,"activeCount":96},[],{"trials":1925,"activeCount":96},[],{"trials":1927,"activeCount":170,"soonestReadout":56},[1928,1938],{"nctId":54,"briefTitle":55,"status":108,"phases":1929,"primaryCompletion":56,"completion":56,"start":1930,"enrollment":1931,"conditions":1932,"interventions":1936},[88],"2020-07-20",336,[1933,1934,1935],"Thyroid; Functional Disturbance","Hypothyroidism","Hemodialysis",[57,1937],"Placebos",{"nctId":1939,"briefTitle":1940,"status":1941,"phases":1942,"primaryCompletion":672,"completion":672,"start":1943,"enrollment":219,"conditions":1944,"interventions":1947},"NCT03191188","A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis Patients","UNKNOWN",[88],"2017-07-01",[1945,1946],"Thyroid Disease","Kidney Diseases, Chronic",[57],{"intervention":1937,"totalTrials":170,"cells":1949},{"EARLY_PHASE1":1950,"PHASE1":1952,"PHASE2":1954,"PHASE3":1956,"PHASE4":1958,"NA":1960},{"trials":1951,"activeCount":96},[],{"trials":1953,"activeCount":96},[],{"trials":1955,"activeCount":96},[],{"trials":1957,"activeCount":96},[],{"trials":1959,"activeCount":96},[],{"trials":1961,"activeCount":170,"soonestReadout":56},[1962],{"nctId":54,"briefTitle":55,"status":108,"phases":1963,"primaryCompletion":56,"completion":56,"start":1930,"enrollment":1931,"conditions":1964,"interventions":1965},[88],[1933,1934,1935],[57,1937],{"intervention":1967,"totalTrials":170,"cells":1968},"Daily low-dose PDE5 inhibitor therapy",{"EARLY_PHASE1":1969,"PHASE1":1971,"PHASE2":1973,"PHASE3":1975,"PHASE4":1977,"NA":1979},{"trials":1970,"activeCount":96},[],{"trials":1972,"activeCount":96},[],{"trials":1974,"activeCount":96},[],{"trials":1976,"activeCount":96},[],{"trials":1978,"activeCount":96},[],{"trials":1980,"activeCount":170,"soonestReadout":281},[1981],{"nctId":1982,"briefTitle":1983,"status":108,"phases":1984,"primaryCompletion":281,"completion":281,"start":1985,"enrollment":113,"conditions":1986,"interventions":1990},"NCT06720597","EndoPAT Device for Endothelial Dysfunction in ED",[88],"2025-08-13",[1987,1988,1989],"Erectile Dysfunction","Hypogonadism, Male","Endothelial Dysfunction",[1967,1991],"Testosterone therapy as per clinical guidelines.",{"intervention":1991,"totalTrials":170,"cells":1993},{"EARLY_PHASE1":1994,"PHASE1":1996,"PHASE2":1998,"PHASE3":2000,"PHASE4":2002,"NA":2004},{"trials":1995,"activeCount":96},[],{"trials":1997,"activeCount":96},[],{"trials":1999,"activeCount":96},[],{"trials":2001,"activeCount":96},[],{"trials":2003,"activeCount":96},[],{"trials":2005,"activeCount":170,"soonestReadout":281},[2006],{"nctId":1982,"briefTitle":1983,"status":108,"phases":2007,"primaryCompletion":281,"completion":281,"start":1985,"enrollment":113,"conditions":2008,"interventions":2009},[88],[1987,1988,1989],[1967,1991],{"intervention":2011,"totalTrials":92,"cells":2012},"OnabotulinumtoxinA",{"EARLY_PHASE1":2013,"PHASE1":2015,"PHASE2":2017,"PHASE3":2032,"PHASE4":2034,"NA":2046},{"trials":2014,"activeCount":96},[],{"trials":2016,"activeCount":96},[],{"trials":2018,"activeCount":96},[2019],{"nctId":2020,"briefTitle":2021,"status":150,"phases":2022,"primaryCompletion":2023,"completion":2024,"start":2025,"enrollment":2026,"conditions":2027,"interventions":2031},"NCT03055767","Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Study in the Pediatric Pain Population",[85],"2018-11-30","2020-04-20","2017-03-01",17,[2028,2029,2030],"Migraine Disorders","Headache, Migraine","Pediatrics",[2011],{"trials":2033,"activeCount":96},[],{"trials":2035,"activeCount":96},[2036],{"nctId":2037,"briefTitle":2038,"status":150,"phases":2039,"primaryCompletion":2040,"completion":2040,"start":2041,"enrollment":1444,"conditions":2042,"interventions":2044},"NCT03373162","Functional Effects of Botox on the Brain Using MRS and fMRI",[87],"2018-03-16","2017-09-30",[2043],"Healthy",[2045],"onabotulinumtoxinA",{"trials":2047,"activeCount":96},[],{"intervention":2049,"totalTrials":170,"cells":2050},"Standard Preparation",{"EARLY_PHASE1":2051,"PHASE1":2053,"PHASE2":2055,"PHASE3":2057,"PHASE4":2059,"NA":2072},{"trials":2052,"activeCount":96},[],{"trials":2054,"activeCount":96},[],{"trials":2056,"activeCount":96},[],{"trials":2058,"activeCount":96},[],{"trials":2060,"activeCount":96},[2061],{"nctId":2062,"briefTitle":2063,"status":150,"phases":2064,"primaryCompletion":2065,"completion":2066,"start":2067,"enrollment":2068,"conditions":2069,"interventions":2071},"NCT02682498","Comparing Post-Op Narcotic Usage in Patients Receiving Periarticular Exparel vs. Standard Periarticular Joint Inj",[87],"2015-07","2015-08","2013-10",38,[2070],"Arthroplasty, Replacement, Knee",[2049],{"trials":2073,"activeCount":96},[],{"intervention":2075,"totalTrials":170,"cells":2076},"OnabotulinumtoxinA 100 UNT [Botox]",{"EARLY_PHASE1":2077,"PHASE1":2079,"PHASE2":2081,"PHASE3":2083,"PHASE4":2085,"NA":2104},{"trials":2078,"activeCount":96},[],{"trials":2080,"activeCount":96},[],{"trials":2082,"activeCount":96},[],{"trials":2084,"activeCount":96},[],{"trials":2086,"activeCount":96},[2087],{"nctId":2088,"briefTitle":2089,"status":150,"phases":2090,"primaryCompletion":2091,"completion":2092,"start":2093,"enrollment":2094,"conditions":2095,"interventions":2103},"NCT05308979","Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial",[87],"2023-12-31","2024-03-31","2022-05-01",116,[2096,2097,2098,2099,2100,2101,2102],"Overactive Bladder","Urinary Urge Incontinence","Overactive Bladder Syndrome","Urinary Incontinence, Urge","Urge Incontinence","Urinary Urgency","Urinary Frequency",[2075],{"trials":2105,"activeCount":96},[],{"intervention":2107,"totalTrials":170,"cells":2108},"Meperidine, Midazolam",{"EARLY_PHASE1":2109,"PHASE1":2111,"PHASE2":2113,"PHASE3":2115,"PHASE4":2117,"NA":2131},{"trials":2110,"activeCount":96},[],{"trials":2112,"activeCount":96},[],{"trials":2114,"activeCount":96},[],{"trials":2116,"activeCount":96},[],{"trials":2118,"activeCount":96},[2119],{"nctId":2120,"briefTitle":2121,"status":150,"phases":2122,"primaryCompletion":2123,"completion":2123,"start":673,"enrollment":2124,"conditions":2125,"interventions":2128},"NCT00937924","Adjunct Sedatives in Endoscopic Ultrasound (EUS) and Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures",[87],"2012-06",304,[2126,2127],"Endoscopic Ultrasound (EUS)","Endoscopic Retrograde Cholangiopancreatography (ERCP)",[2107,2129,2130],"Diphenhydramine","Promethazine",{"trials":2132,"activeCount":96},[],{"intervention":2129,"totalTrials":170,"cells":2134},{"EARLY_PHASE1":2135,"PHASE1":2137,"PHASE2":2139,"PHASE3":2141,"PHASE4":2143,"NA":2149},{"trials":2136,"activeCount":96},[],{"trials":2138,"activeCount":96},[],{"trials":2140,"activeCount":96},[],{"trials":2142,"activeCount":96},[],{"trials":2144,"activeCount":96},[2145],{"nctId":2120,"briefTitle":2121,"status":150,"phases":2146,"primaryCompletion":2123,"completion":2123,"start":673,"enrollment":2124,"conditions":2147,"interventions":2148},[87],[2126,2127],[2107,2129,2130],{"trials":2150,"activeCount":96},[],{"intervention":2130,"totalTrials":170,"cells":2152},{"EARLY_PHASE1":2153,"PHASE1":2155,"PHASE2":2157,"PHASE3":2159,"PHASE4":2161,"NA":2167},{"trials":2154,"activeCount":96},[],{"trials":2156,"activeCount":96},[],{"trials":2158,"activeCount":96},[],{"trials":2160,"activeCount":96},[],{"trials":2162,"activeCount":96},[2163],{"nctId":2120,"briefTitle":2121,"status":150,"phases":2164,"primaryCompletion":2123,"completion":2123,"start":673,"enrollment":2124,"conditions":2165,"interventions":2166},[87],[2126,2127],[2107,2129,2130],{"trials":2168,"activeCount":96},[],{"intervention":2170,"totalTrials":170,"cells":2171},"Polyethylene Glycol 3350",{"EARLY_PHASE1":2172,"PHASE1":2174,"PHASE2":2176,"PHASE3":2178,"PHASE4":2180,"NA":2196},{"trials":2173,"activeCount":96},[],{"trials":2175,"activeCount":96},[],{"trials":2177,"activeCount":96},[],{"trials":2179,"activeCount":96},[],{"trials":2181,"activeCount":96},[2182],{"nctId":2183,"briefTitle":2184,"status":972,"phases":2185,"primaryCompletion":2186,"completion":2186,"start":2187,"enrollment":2188,"conditions":2189,"interventions":2192},"NCT04585542","Comparison of Potassium Binders in the ER",[87],"2025-01-31","2020-10-20",37,[2190,2191],"Acute Hyperkalemia","Oral Potassium Binders",[2170,2193,2194,2195],"Sodium Polystyrene Sulfonate Oral Suspension [SPS]","Patiromer","Sodium zirconium cyclosilicate",{"trials":2197,"activeCount":96},[],{"intervention":2193,"totalTrials":170,"cells":2199},{"EARLY_PHASE1":2200,"PHASE1":2202,"PHASE2":2204,"PHASE3":2206,"PHASE4":2208,"NA":2214},{"trials":2201,"activeCount":96},[],{"trials":2203,"activeCount":96},[],{"trials":2205,"activeCount":96},[],{"trials":2207,"activeCount":96},[],{"trials":2209,"activeCount":96},[2210],{"nctId":2183,"briefTitle":2184,"status":972,"phases":2211,"primaryCompletion":2186,"completion":2186,"start":2187,"enrollment":2188,"conditions":2212,"interventions":2213},[87],[2190,2191],[2170,2193,2194,2195],{"trials":2215,"activeCount":96},[],{"intervention":2194,"totalTrials":170,"cells":2217},{"EARLY_PHASE1":2218,"PHASE1":2220,"PHASE2":2222,"PHASE3":2224,"PHASE4":2226,"NA":2232},{"trials":2219,"activeCount":96},[],{"trials":2221,"activeCount":96},[],{"trials":2223,"activeCount":96},[],{"trials":2225,"activeCount":96},[],{"trials":2227,"activeCount":96},[2228],{"nctId":2183,"briefTitle":2184,"status":972,"phases":2229,"primaryCompletion":2186,"completion":2186,"start":2187,"enrollment":2188,"conditions":2230,"interventions":2231},[87],[2190,2191],[2170,2193,2194,2195],{"trials":2233,"activeCount":96},[],{"intervention":2195,"totalTrials":170,"cells":2235},{"EARLY_PHASE1":2236,"PHASE1":2238,"PHASE2":2240,"PHASE3":2242,"PHASE4":2244,"NA":2250},{"trials":2237,"activeCount":96},[],{"trials":2239,"activeCount":96},[],{"trials":2241,"activeCount":96},[],{"trials":2243,"activeCount":96},[],{"trials":2245,"activeCount":96},[2246],{"nctId":2183,"briefTitle":2184,"status":972,"phases":2247,"primaryCompletion":2186,"completion":2186,"start":2187,"enrollment":2188,"conditions":2248,"interventions":2249},[87],[2190,2191],[2170,2193,2194,2195],{"trials":2251,"activeCount":96},[],{"intervention":2253,"totalTrials":170,"cells":2254},"Cialis 5Mg",{"EARLY_PHASE1":2255,"PHASE1":2257,"PHASE2":2259,"PHASE3":2261,"PHASE4":2263,"NA":2277},{"trials":2256,"activeCount":96},[],{"trials":2258,"activeCount":96},[],{"trials":2260,"activeCount":96},[],{"trials":2262,"activeCount":96},[],{"trials":2264,"activeCount":96},[2265],{"nctId":2266,"briefTitle":2267,"status":150,"phases":2268,"primaryCompletion":2269,"completion":2269,"start":2270,"enrollment":2271,"conditions":2272,"interventions":2274},"NCT03229889","Trial of Tadalafil, Tamsulosin and Combination for Access Sheath Deployment",[87],"2022-03-24","2017-06-07",220,[2273],"Nephrolithiasis",[2253,2275,2276],"Flomax 0.4Mg","Cialis + Flomax",{"trials":2278,"activeCount":96},[],{"intervention":2275,"totalTrials":170,"cells":2280},{"EARLY_PHASE1":2281,"PHASE1":2283,"PHASE2":2285,"PHASE3":2287,"PHASE4":2289,"NA":2295},{"trials":2282,"activeCount":96},[],{"trials":2284,"activeCount":96},[],{"trials":2286,"activeCount":96},[],{"trials":2288,"activeCount":96},[],{"trials":2290,"activeCount":96},[2291],{"nctId":2266,"briefTitle":2267,"status":150,"phases":2292,"primaryCompletion":2269,"completion":2269,"start":2270,"enrollment":2271,"conditions":2293,"interventions":2294},[87],[2273],[2253,2275,2276],{"trials":2296,"activeCount":96},[],{"intervention":2276,"totalTrials":170,"cells":2298},{"EARLY_PHASE1":2299,"PHASE1":2301,"PHASE2":2303,"PHASE3":2305,"PHASE4":2307,"NA":2313},{"trials":2300,"activeCount":96},[],{"trials":2302,"activeCount":96},[],{"trials":2304,"activeCount":96},[],{"trials":2306,"activeCount":96},[],{"trials":2308,"activeCount":96},[2309],{"nctId":2266,"briefTitle":2267,"status":150,"phases":2310,"primaryCompletion":2269,"completion":2269,"start":2270,"enrollment":2271,"conditions":2311,"interventions":2312},[87],[2273],[2253,2275,2276],{"trials":2314,"activeCount":96},[],{"intervention":2316,"totalTrials":170,"cells":2317},"Lidocaine patch 5%",{"EARLY_PHASE1":2318,"PHASE1":2320,"PHASE2":2322,"PHASE3":2324,"PHASE4":2326,"NA":2339},{"trials":2319,"activeCount":96},[],{"trials":2321,"activeCount":96},[],{"trials":2323,"activeCount":96},[],{"trials":2325,"activeCount":96},[],{"trials":2327,"activeCount":96},[2328],{"nctId":2329,"briefTitle":2330,"status":2331,"phases":2332,"primaryCompletion":2333,"completion":2333,"start":2334,"enrollment":96,"conditions":2335,"interventions":2338},"NCT05151510","Trigger Point Injections Versus Lidocaine Patch for Myofascial Pain in the Emergency Department","WITHDRAWN",[87],"2022-06-30","2021-11-01",[2336,2337],"Myofascial Trigger Point Pain","Myofacial Pain",[2316],{"trials":2340,"activeCount":96},[],{"intervention":2342,"totalTrials":170,"cells":2343},"Aminolevulinic Acid",{"EARLY_PHASE1":2344,"PHASE1":2346,"PHASE2":2348,"PHASE3":2350,"PHASE4":2352,"NA":2363},{"trials":2345,"activeCount":96},[],{"trials":2347,"activeCount":96},[],{"trials":2349,"activeCount":96},[],{"trials":2351,"activeCount":96},[],{"trials":2353,"activeCount":96},[2354],{"nctId":2355,"briefTitle":2356,"status":150,"phases":2357,"primaryCompletion":2358,"completion":2359,"start":661,"enrollment":895,"conditions":2360,"interventions":2362},"NCT03327831","Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses",[87],"2017-02","2017-07",[2361],"Actinic Keratosis",[2342],{"trials":2364,"activeCount":96},[],{"intervention":158,"totalTrials":170,"cells":2366},{"EARLY_PHASE1":2367,"PHASE1":2369,"PHASE2":2371,"PHASE3":2373,"PHASE4":2375,"NA":2381},{"trials":2368,"activeCount":96},[],{"trials":2370,"activeCount":96},[],{"trials":2372,"activeCount":96},[],{"trials":2374,"activeCount":96},[],{"trials":2376,"activeCount":96},[2377],{"nctId":148,"briefTitle":149,"status":150,"phases":2378,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":2379,"interventions":2380},[87],[156,127],[135,158],{"trials":2382,"activeCount":96},[],{"intervention":2384,"totalTrials":170,"cells":2385},"Zolpidem",{"EARLY_PHASE1":2386,"PHASE1":2388,"PHASE2":2390,"PHASE3":2392,"PHASE4":2394,"NA":2405},{"trials":2387,"activeCount":96},[],{"trials":2389,"activeCount":96},[],{"trials":2391,"activeCount":96},[],{"trials":2393,"activeCount":96},[],{"trials":2395,"activeCount":96},[2396],{"nctId":2397,"briefTitle":2398,"status":972,"phases":2399,"primaryCompletion":2400,"completion":2400,"start":2401,"enrollment":1444,"conditions":2402,"interventions":2404},"NCT03657212","Enhancing Memory Consolidation in Older Adults",[87],"2019-01-01","2018-10-01",[2403],"Aging",[2384],{"trials":2406,"activeCount":96},[],{"intervention":2408,"totalTrials":170,"cells":2409},"Retapamulin",{"EARLY_PHASE1":2410,"PHASE1":2412,"PHASE2":2414,"PHASE3":2416,"PHASE4":2418,"NA":2430},{"trials":2411,"activeCount":96},[],{"trials":2413,"activeCount":96},[],{"trials":2415,"activeCount":96},[],{"trials":2417,"activeCount":96},[],{"trials":2419,"activeCount":96},[2420],{"nctId":2421,"briefTitle":2422,"status":150,"phases":2423,"primaryCompletion":2424,"completion":2424,"start":2425,"enrollment":2426,"conditions":2427,"interventions":2429},"NCT01461668","Retapamulin for Reducing MRSA Nasal Carriage",[87],"2017-12","2012-07",53,[2428],"Methicillin-Resistant Staphylococcus Aureus",[2408],{"trials":2431,"activeCount":96},[],{"intervention":2433,"totalTrials":170,"cells":2434},"Dexmedetomidine",{"EARLY_PHASE1":2435,"PHASE1":2437,"PHASE2":2439,"PHASE3":2441,"PHASE4":2443,"NA":2455},{"trials":2436,"activeCount":96},[],{"trials":2438,"activeCount":96},[],{"trials":2440,"activeCount":96},[],{"trials":2442,"activeCount":96},[],{"trials":2444,"activeCount":96},[2445],{"nctId":2446,"briefTitle":2447,"status":150,"phases":2448,"primaryCompletion":2449,"completion":2449,"start":2450,"enrollment":2451,"conditions":2452,"interventions":2454},"NCT05321121","Dexmedotomidine for Acute Pain Control in Patients With Multiple Rib FracturesRandomized Controlled Trial",[87],"2023-10-21","2021-11-12",41,[445,2453],"Pain, Acute",[2433],{"trials":2456,"activeCount":96},[],{"intervention":2458,"totalTrials":170,"cells":2459},"Chlorhexidine gluconate",{"EARLY_PHASE1":2460,"PHASE1":2462,"PHASE2":2464,"PHASE3":2466,"PHASE4":2468,"NA":2482},{"trials":2461,"activeCount":96},[],{"trials":2463,"activeCount":96},[],{"trials":2465,"activeCount":96},[],{"trials":2467,"activeCount":96},[],{"trials":2469,"activeCount":96},[2470],{"nctId":2471,"briefTitle":2472,"status":150,"phases":2473,"primaryCompletion":2474,"completion":2474,"start":2475,"enrollment":2476,"conditions":2477,"interventions":2480},"NCT03118232","Project PROTECT: Protecting Nursing Homes From Infections and Hospitalization",[87],"2023-10-10","2017-04-03",13952,[2478,2479],"Hospitalization","Infection",[2458,2481],"Iodophor",{"trials":2483,"activeCount":96},[],{"intervention":2481,"totalTrials":170,"cells":2485},{"EARLY_PHASE1":2486,"PHASE1":2488,"PHASE2":2490,"PHASE3":2492,"PHASE4":2494,"NA":2500},{"trials":2487,"activeCount":96},[],{"trials":2489,"activeCount":96},[],{"trials":2491,"activeCount":96},[],{"trials":2493,"activeCount":96},[],{"trials":2495,"activeCount":96},[2496],{"nctId":2471,"briefTitle":2472,"status":150,"phases":2497,"primaryCompletion":2474,"completion":2474,"start":2475,"enrollment":2476,"conditions":2498,"interventions":2499},[87],[2478,2479],[2458,2481],{"trials":2501,"activeCount":96},[],{"intervention":2503,"totalTrials":170,"cells":2504},"Risperidone",{"EARLY_PHASE1":2505,"PHASE1":2507,"PHASE2":2509,"PHASE3":2511,"PHASE4":2513,"NA":2526},{"trials":2506,"activeCount":96},[],{"trials":2508,"activeCount":96},[],{"trials":2510,"activeCount":96},[],{"trials":2512,"activeCount":96},[],{"trials":2514,"activeCount":96},[2515],{"nctId":2516,"briefTitle":2517,"status":1941,"phases":2518,"primaryCompletion":2519,"completion":2520,"start":2521,"enrollment":219,"conditions":2522,"interventions":2524},"NCT00937261","Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning",[87],"2010-07","2011-01","2009-07",[2523],"Schizophrenia",[2503,2525],"Paliperidone",{"trials":2527,"activeCount":96},[],{"intervention":2525,"totalTrials":170,"cells":2529},{"EARLY_PHASE1":2530,"PHASE1":2532,"PHASE2":2534,"PHASE3":2536,"PHASE4":2538,"NA":2544},{"trials":2531,"activeCount":96},[],{"trials":2533,"activeCount":96},[],{"trials":2535,"activeCount":96},[],{"trials":2537,"activeCount":96},[],{"trials":2539,"activeCount":96},[2540],{"nctId":2516,"briefTitle":2517,"status":1941,"phases":2541,"primaryCompletion":2519,"completion":2520,"start":2521,"enrollment":219,"conditions":2542,"interventions":2543},[87],[2523],[2503,2525],{"trials":2545,"activeCount":96},[],{"intervention":2547,"totalTrials":170,"cells":2548},"Calcium Gluconate",{"EARLY_PHASE1":2549,"PHASE1":2551,"PHASE2":2553,"PHASE3":2555,"PHASE4":2569,"NA":2571},{"trials":2550,"activeCount":96},[],{"trials":2552,"activeCount":96},[],{"trials":2554,"activeCount":96},[],{"trials":2556,"activeCount":96},[2557],{"nctId":2558,"briefTitle":2559,"status":2331,"phases":2560,"primaryCompletion":2561,"completion":123,"start":2562,"enrollment":96,"conditions":2563,"interventions":2568},"NCT05953376","Empiric Calcium in Massive Transfusion",[86],"2025-12","2025-01",[2564,2565,2566,2567],"Hemorrhage","Trauma","Hypocalcemia","Shock, Hemorrhagic",[2547],{"trials":2570,"activeCount":96},[],{"trials":2572,"activeCount":96},[],{"intervention":2574,"totalTrials":170,"cells":2575},"Lurasidone 80 mg",{"EARLY_PHASE1":2576,"PHASE1":2578,"PHASE2":2580,"PHASE3":2582,"PHASE4":2594,"NA":2596},{"trials":2577,"activeCount":96},[],{"trials":2579,"activeCount":96},[],{"trials":2581,"activeCount":96},[],{"trials":2583,"activeCount":96},[2584],{"nctId":2585,"briefTitle":2586,"status":150,"phases":2587,"primaryCompletion":2067,"start":2588,"enrollment":2589,"conditions":2590,"interventions":2591},"NCT01979679","A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone",[86],"2008-12",28,[2523],[2574,2592,2593],"Lurasidone 120 mg","Lurasidone 160 mg",{"trials":2595,"activeCount":96},[],{"trials":2597,"activeCount":96},[],{"intervention":2592,"totalTrials":170,"cells":2599},{"EARLY_PHASE1":2600,"PHASE1":2602,"PHASE2":2604,"PHASE3":2606,"PHASE4":2612,"NA":2614},{"trials":2601,"activeCount":96},[],{"trials":2603,"activeCount":96},[],{"trials":2605,"activeCount":96},[],{"trials":2607,"activeCount":96},[2608],{"nctId":2585,"briefTitle":2586,"status":150,"phases":2609,"primaryCompletion":2067,"start":2588,"enrollment":2589,"conditions":2610,"interventions":2611},[86],[2523],[2574,2592,2593],{"trials":2613,"activeCount":96},[],{"trials":2615,"activeCount":96},[],{"intervention":2593,"totalTrials":170,"cells":2617},{"EARLY_PHASE1":2618,"PHASE1":2620,"PHASE2":2622,"PHASE3":2624,"PHASE4":2630,"NA":2632},{"trials":2619,"activeCount":96},[],{"trials":2621,"activeCount":96},[],{"trials":2623,"activeCount":96},[],{"trials":2625,"activeCount":96},[2626],{"nctId":2585,"briefTitle":2586,"status":150,"phases":2627,"primaryCompletion":2067,"start":2588,"enrollment":2589,"conditions":2628,"interventions":2629},[86],[2523],[2574,2592,2593],{"trials":2631,"activeCount":96},[],{"trials":2633,"activeCount":96},[],{"intervention":2635,"totalTrials":170,"cells":2636},"Asenapine",{"EARLY_PHASE1":2637,"PHASE1":2639,"PHASE2":2641,"PHASE3":2643,"PHASE4":2656,"NA":2658},{"trials":2638,"activeCount":96},[],{"trials":2640,"activeCount":96},[],{"trials":2642,"activeCount":96},[],{"trials":2644,"activeCount":96},[2645],{"nctId":2646,"briefTitle":2647,"status":2648,"phases":2649,"primaryCompletion":2650,"completion":2650,"start":2651,"enrollment":2652,"conditions":2653,"interventions":2655},"NCT01684657","A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering","SUSPENDED",[86],"2014-05","2012-09",32,[2654],"Stuttering",[2635],{"trials":2657,"activeCount":96},[],{"trials":2659,"activeCount":96},[],{"intervention":2661,"totalTrials":170,"cells":2662},"Botox",{"EARLY_PHASE1":2663,"PHASE1":2665,"PHASE2":2667,"PHASE3":2669,"PHASE4":2680,"NA":2682},{"trials":2664,"activeCount":96},[],{"trials":2666,"activeCount":96},[],{"trials":2668,"activeCount":96},[],{"trials":2670,"activeCount":96},[2671],{"nctId":2672,"briefTitle":2673,"status":972,"phases":2674,"primaryCompletion":2358,"completion":2358,"start":2675,"enrollment":759,"conditions":2676,"interventions":2679},"NCT02078895","Randomization of Botox for Stent Pain and Irritative Voiding Symptoms",[86],"2014-02",[2677,2678],"Lower Urinary Tract Discomfort","Stent Pain",[2661],{"trials":2681,"activeCount":96},[],{"trials":2683,"activeCount":96},[],{"intervention":2685,"totalTrials":170,"cells":2686},"[F-18] FLT",{"EARLY_PHASE1":2687,"PHASE1":2689,"PHASE2":2691,"PHASE3":2693,"PHASE4":2703,"NA":2705},{"trials":2688,"activeCount":96},[],{"trials":2690,"activeCount":96},[],{"trials":2692,"activeCount":96},[],{"trials":2694,"activeCount":96},[2695],{"nctId":2696,"briefTitle":2697,"status":2331,"phases":2698,"primaryCompletion":2699,"completion":2699,"start":2700,"enrollment":96,"conditions":2701,"interventions":2702},"NCT00894101","Positron Emission Tomography Imaging With [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation",[85,86],"2010-04","2009-05",[863],[2685],{"trials":2704,"activeCount":96},[],{"trials":2706,"activeCount":96},[],{"intervention":2708,"totalTrials":170,"cells":2709},"Bupivacaine",{"EARLY_PHASE1":2710,"PHASE1":2712,"PHASE2":2714,"PHASE3":2716,"PHASE4":2729,"NA":2731},{"trials":2711,"activeCount":96},[],{"trials":2713,"activeCount":96},[],{"trials":2715,"activeCount":96},[],{"trials":2717,"activeCount":96},[2718],{"nctId":2719,"briefTitle":2720,"status":972,"phases":2721,"primaryCompletion":2722,"completion":2722,"start":2723,"enrollment":16,"conditions":2724,"interventions":2727},"NCT04849858","Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures",[86],"2023-01-13","2019-05-20",[864,2725,2726],"Fibroids","Uterine Cancer",[2708,2728,2728],"Liposomal bupivacaine",{"trials":2730,"activeCount":96},[],{"trials":2732,"activeCount":96},[],{"intervention":2728,"totalTrials":170,"cells":2734},{"EARLY_PHASE1":2735,"PHASE1":2737,"PHASE2":2739,"PHASE3":2741,"PHASE4":2747,"NA":2749},{"trials":2736,"activeCount":96},[],{"trials":2738,"activeCount":96},[],{"trials":2740,"activeCount":96},[],{"trials":2742,"activeCount":96},[2743],{"nctId":2719,"briefTitle":2720,"status":972,"phases":2744,"primaryCompletion":2722,"completion":2722,"start":2723,"enrollment":16,"conditions":2745,"interventions":2746},[86],[864,2725,2726],[2708,2728,2728],{"trials":2748,"activeCount":96},[],{"trials":2750,"activeCount":96},[],{"intervention":1525,"totalTrials":606,"cells":2752},{"EARLY_PHASE1":2753,"PHASE1":2755,"PHASE2":2757,"PHASE3":2784,"PHASE4":2786,"NA":2788},{"trials":2754,"activeCount":96},[],{"trials":2756,"activeCount":96},[],{"trials":2758,"activeCount":96},[2759,2771,2775],{"nctId":2760,"briefTitle":2761,"status":972,"phases":2762,"primaryCompletion":2763,"completion":2763,"start":2764,"enrollment":543,"conditions":2765,"interventions":2768},"NCT00256321","Celecoxib\u002FOxaliplatin\u002FCapecitabine for Gastric\u002FGastroesophageal Junction Carcinoma",[85],"2007-08","2004-10",[2766,2767],"Gastric Carcinoma","Gastroesophageal Junction Carcinoma",[1525,2769,2770],"Capecitabine","Celecoxib",{"nctId":1516,"briefTitle":1517,"status":972,"phases":2772,"primaryCompletion":1519,"completion":1519,"start":1520,"enrollment":543,"conditions":2773,"interventions":2774},[85],[1522,1523],[1525,1486],{"nctId":2776,"briefTitle":2777,"status":972,"phases":2778,"primaryCompletion":2779,"completion":2780,"start":2781,"enrollment":25,"conditions":2782,"interventions":2783},"NCT00256308","Adjuvant Chemoradiation With Weekly Oxaliplatin in Resected Head and Neck Cancer",[85],"2010-05","2011-10","2005-02",[863],[1525],{"trials":2785,"activeCount":96},[],{"trials":2787,"activeCount":96},[],{"trials":2789,"activeCount":96},[],{"intervention":2769,"totalTrials":92,"cells":2791},{"EARLY_PHASE1":2792,"PHASE1":2794,"PHASE2":2796,"PHASE3":2812,"PHASE4":2814,"NA":2816},{"trials":2793,"activeCount":96},[],{"trials":2795,"activeCount":96},[],{"trials":2797,"activeCount":96},[2798,2808],{"nctId":2799,"briefTitle":2800,"status":150,"phases":2801,"primaryCompletion":2802,"completion":2802,"start":2803,"enrollment":2804,"conditions":2805,"interventions":2806},"NCT00257348","Capecitabine and Docetaxel in Advanced\u002FRecurrent Cervical Cancer",[85],"2007-07","2004-03",5,[24],[2769,2807],"Docetaxel",{"nctId":2760,"briefTitle":2761,"status":972,"phases":2809,"primaryCompletion":2763,"completion":2763,"start":2764,"enrollment":543,"conditions":2810,"interventions":2811},[85],[2766,2767],[1525,2769,2770],{"trials":2813,"activeCount":96},[],{"trials":2815,"activeCount":96},[],{"trials":2817,"activeCount":96},[],{"intervention":2807,"totalTrials":92,"cells":2819},{"EARLY_PHASE1":2820,"PHASE1":2822,"PHASE2":2824,"PHASE3":2844,"PHASE4":2846,"NA":2848},{"trials":2821,"activeCount":96},[],{"trials":2823,"activeCount":96},[],{"trials":2825,"activeCount":96},[2826,2830],{"nctId":2799,"briefTitle":2800,"status":150,"phases":2827,"primaryCompletion":2802,"completion":2802,"start":2803,"enrollment":2804,"conditions":2828,"interventions":2829},[85],[24],[2769,2807],{"nctId":2831,"briefTitle":2832,"status":150,"phases":2833,"primaryCompletion":2834,"completion":2834,"start":2835,"enrollment":591,"conditions":2836,"interventions":2843},"NCT01882985","Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients",[85],"2016-10","2010-12",[2837,2838,2839,2840,2841,2842],"Adenocarcinoma of the Prostate","Recurrent Prostate Cancer","Stage I Prostate Cancer","Stage IIA Prostate Cancer","Stage IIB Prostate Cancer","Stage III Prostate Cancer",[2807],{"trials":2845,"activeCount":96},[],{"trials":2847,"activeCount":96},[],{"trials":2849,"activeCount":96},[],{"intervention":2851,"totalTrials":92,"cells":2852},"Nicotinamide",{"EARLY_PHASE1":2853,"PHASE1":2855,"PHASE2":2857,"PHASE3":2878,"PHASE4":2880,"NA":2882},{"trials":2854,"activeCount":96},[],{"trials":2856,"activeCount":96},[],{"trials":2858,"activeCount":96},[2859,2868],{"nctId":2860,"briefTitle":2861,"status":150,"phases":2862,"primaryCompletion":894,"completion":894,"start":2863,"enrollment":1118,"conditions":2864,"interventions":2866},"NCT00580931","Safety Study of Nicotinamide to Treat Alzheimer's Disease",[84,85],"2008-01",[2865],"Alzheimer's Disease",[2851,2867],"Enduramide placebo",{"nctId":2869,"briefTitle":2870,"status":150,"phases":2871,"primaryCompletion":2872,"completion":2872,"start":2873,"enrollment":2874,"conditions":2875,"interventions":2877},"NCT03061474","Nicotinamide as an Early Alzheimer's Disease Treatment",[85],"2022-08-30","2017-07-12",46,[2865,2876],"Mild Cognitive Impairment",[2851],{"trials":2879,"activeCount":96},[],{"trials":2881,"activeCount":96},[],{"trials":2883,"activeCount":96},[],{"intervention":700,"totalTrials":92,"cells":2885},{"EARLY_PHASE1":2886,"PHASE1":2888,"PHASE2":2890,"PHASE3":2906,"PHASE4":2908,"NA":2910},{"trials":2887,"activeCount":96},[],{"trials":2889,"activeCount":96},[],{"trials":2891,"activeCount":96},[2892,2902],{"nctId":2893,"briefTitle":2894,"status":150,"phases":2895,"primaryCompletion":2896,"completion":2896,"start":2897,"enrollment":560,"conditions":2898,"interventions":2901},"NCT00257322","Cellular Immune Augmentation in Colon and Rectal Cancer",[85],"2007-01","2003-04",[2899,2900],"Colon Cancer","Rectal Cancer",[700],{"nctId":690,"briefTitle":691,"status":150,"phases":2903,"primaryCompletion":693,"completion":693,"start":694,"enrollment":695,"conditions":2904,"interventions":2905},[85],[15],[698,598,37,699,700,573,666],{"trials":2907,"activeCount":96},[],{"trials":2909,"activeCount":96},[],{"trials":2911,"activeCount":96},[],{"intervention":2913,"totalTrials":92,"cells":2914},"Cisplatin",{"EARLY_PHASE1":2915,"PHASE1":2917,"PHASE2":2919,"PHASE3":2939,"PHASE4":2941,"NA":2943},{"trials":2916,"activeCount":96},[],{"trials":2918,"activeCount":96},[],{"trials":2920,"activeCount":96},[2921,2930],{"nctId":2922,"briefTitle":2923,"status":2331,"phases":2924,"primaryCompletion":2925,"completion":2925,"start":2926,"enrollment":96,"conditions":2927,"interventions":2928},"NCT00257829","Improving Tumor Oxygenation in Cervical Cancer",[85],"2006-09-20","2004-07",[24],[2929,2913],"Methazolamide",{"nctId":2931,"briefTitle":2932,"status":150,"phases":2933,"primaryCompletion":2934,"completion":2934,"start":2935,"enrollment":192,"conditions":2936,"interventions":2937},"NCT00257816","Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma",[85],"2007-12-17","2004-01",[24],[2938,2913],"Topotecan",{"trials":2940,"activeCount":96},[],{"trials":2942,"activeCount":96},[],{"trials":2944,"activeCount":96},[],{"intervention":2946,"totalTrials":170,"cells":2947},"Oxaliplatin with Gemcitabine",{"EARLY_PHASE1":2948,"PHASE1":2950,"PHASE2":2952,"PHASE3":2963,"PHASE4":2965,"NA":2967},{"trials":2949,"activeCount":96},[],{"trials":2951,"activeCount":96},[],{"trials":2953,"activeCount":96},[2954],{"nctId":2955,"briefTitle":2956,"status":972,"phases":2957,"primaryCompletion":2958,"completion":2958,"start":2959,"enrollment":2026,"conditions":2960,"interventions":2962},"NCT04039867","Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer",[85],"2011-10-06","2005-01-20",[2961],"Carcinoma, Transitional Cell",[2946],{"trials":2964,"activeCount":96},[],{"trials":2966,"activeCount":96},[],{"trials":2968,"activeCount":96},[],{"intervention":2970,"totalTrials":170,"cells":2971},"Etanercept",{"EARLY_PHASE1":2972,"PHASE1":2974,"PHASE2":2976,"PHASE3":2987,"PHASE4":2989,"NA":2991},{"trials":2973,"activeCount":96},[],{"trials":2975,"activeCount":96},[],{"trials":2977,"activeCount":96},[2978],{"nctId":2979,"briefTitle":2980,"status":150,"phases":2981,"primaryCompletion":2982,"completion":2982,"start":2983,"enrollment":560,"conditions":2984,"interventions":2986},"NCT00585650","Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and\u002For Feet",[84,85],"2008-05","2007-05",[2985],"Psoriasis",[2970],{"trials":2988,"activeCount":96},[],{"trials":2990,"activeCount":96},[],{"trials":2992,"activeCount":96},[],{"intervention":2994,"totalTrials":170,"cells":2995},"Propranolol",{"EARLY_PHASE1":2996,"PHASE1":2998,"PHASE2":3000,"PHASE3":3010,"PHASE4":3012,"NA":3014},{"trials":2997,"activeCount":96},[],{"trials":2999,"activeCount":96},[],{"trials":3001,"activeCount":96},[3002],{"nctId":3003,"briefTitle":3004,"status":2331,"phases":3005,"primaryCompletion":3006,"completion":3006,"start":2935,"enrollment":96,"conditions":3007,"interventions":3009},"NCT00315913","Trial of Oxytocin Alone Versus Oxytocin and Propranolol for the Treatment of Abnormal Labor",[85],"2008-03",[3008],"Dysfunctional Labor",[2994],{"trials":3011,"activeCount":96},[],{"trials":3013,"activeCount":96},[],{"trials":3015,"activeCount":96},[],{"intervention":3017,"totalTrials":170,"cells":3018},"sertraline, lithium",{"EARLY_PHASE1":3019,"PHASE1":3021,"PHASE2":3023,"PHASE3":3036,"PHASE4":3038,"NA":3040},{"trials":3020,"activeCount":96},[],{"trials":3022,"activeCount":96},[],{"trials":3024,"activeCount":96},[3025],{"nctId":3026,"briefTitle":3027,"status":150,"phases":3028,"primaryCompletion":3029,"completion":3029,"start":3030,"enrollment":3031,"conditions":3032,"interventions":3035},"NCT00581009","The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients",[84,85],"2011-12-09","2001-05-30",49,[3033,3034],"Major Depressive Disorder","Bipolar Disorder",[3017],{"trials":3037,"activeCount":96},[],{"trials":3039,"activeCount":96},[],{"trials":3041,"activeCount":96},[],{"intervention":3043,"totalTrials":170,"cells":3044},"Dasatinib",{"EARLY_PHASE1":3045,"PHASE1":3047,"PHASE2":3049,"PHASE3":3060,"PHASE4":3062,"NA":3064},{"trials":3046,"activeCount":96},[],{"trials":3048,"activeCount":96},[],{"trials":3050,"activeCount":96},[3051],{"nctId":3052,"briefTitle":3053,"status":150,"phases":3054,"primaryCompletion":3055,"completion":3055,"start":2802,"enrollment":2068,"conditions":3056,"interventions":3059},"NCT00570700","Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer",[85],"2012-02",[3057,2837,3058,22,2838],"Hormone-refractory Prostate Cancer","Hormone-resistant Prostate Cancer",[3043],{"trials":3061,"activeCount":96},[],{"trials":3063,"activeCount":96},[],{"trials":3065,"activeCount":96},[],{"intervention":2867,"totalTrials":170,"cells":3067},{"EARLY_PHASE1":3068,"PHASE1":3070,"PHASE2":3072,"PHASE3":3078,"PHASE4":3080,"NA":3082},{"trials":3069,"activeCount":96},[],{"trials":3071,"activeCount":96},[],{"trials":3073,"activeCount":96},[3074],{"nctId":2860,"briefTitle":2861,"status":150,"phases":3075,"primaryCompletion":894,"completion":894,"start":2863,"enrollment":1118,"conditions":3076,"interventions":3077},[84,85],[2865],[2851,2867],{"trials":3079,"activeCount":96},[],{"trials":3081,"activeCount":96},[],{"trials":3083,"activeCount":96},[],{"intervention":2770,"totalTrials":170,"cells":3085},{"EARLY_PHASE1":3086,"PHASE1":3088,"PHASE2":3090,"PHASE3":3096,"PHASE4":3098,"NA":3100},{"trials":3087,"activeCount":96},[],{"trials":3089,"activeCount":96},[],{"trials":3091,"activeCount":96},[3092],{"nctId":2760,"briefTitle":2761,"status":972,"phases":3093,"primaryCompletion":2763,"completion":2763,"start":2764,"enrollment":543,"conditions":3094,"interventions":3095},[85],[2766,2767],[1525,2769,2770],{"trials":3097,"activeCount":96},[],{"trials":3099,"activeCount":96},[],{"trials":3101,"activeCount":96},[],{"intervention":2929,"totalTrials":170,"cells":3103},{"EARLY_PHASE1":3104,"PHASE1":3106,"PHASE2":3108,"PHASE3":3114,"PHASE4":3116,"NA":3118},{"trials":3105,"activeCount":96},[],{"trials":3107,"activeCount":96},[],{"trials":3109,"activeCount":96},[3110],{"nctId":2922,"briefTitle":2923,"status":2331,"phases":3111,"primaryCompletion":2925,"completion":2925,"start":2926,"enrollment":96,"conditions":3112,"interventions":3113},[85],[24],[2929,2913],{"trials":3115,"activeCount":96},[],{"trials":3117,"activeCount":96},[],{"trials":3119,"activeCount":96},[],{"intervention":3121,"totalTrials":170,"cells":3122},"Midazolam",{"EARLY_PHASE1":3123,"PHASE1":3125,"PHASE2":3127,"PHASE3":3143,"PHASE4":3145,"NA":3147},{"trials":3124,"activeCount":96},[],{"trials":3126,"activeCount":96},[],{"trials":3128,"activeCount":96},[3129],{"nctId":3130,"briefTitle":3131,"status":150,"phases":3132,"primaryCompletion":3133,"completion":3133,"start":2897,"enrollment":3134,"conditions":3135,"interventions":3142},"NCT00581139","Psychological Influences on Postoperative Recovery",[85],"2009-04",241,[3136,3137,3138,3139,3140,3141],"Care, Postoperative","Pain, Postoperative","Surgical Procedures, Operative","Otorhinolaryngologic Surgical Procedures","Tonsillectomy","Adenoidectomy",[3121],{"trials":3144,"activeCount":96},[],{"trials":3146,"activeCount":96},[],{"trials":3148,"activeCount":96},[],{"intervention":3150,"totalTrials":170,"cells":3151},"Aspirin",{"EARLY_PHASE1":3152,"PHASE1":3154,"PHASE2":3156,"PHASE3":3166,"PHASE4":3168,"NA":3170},{"trials":3153,"activeCount":96},[],{"trials":3155,"activeCount":96},[],{"trials":3157,"activeCount":96},[3158],{"nctId":3159,"briefTitle":3160,"status":150,"phases":3161,"primaryCompletion":3162,"completion":3162,"start":3163,"enrollment":859,"conditions":3164,"interventions":3165},"NCT00578721","Trial of Aspirin and Arginine Restriction in Colorectal Cancer",[85],"2013-11-26","2008-09-24",[31],[3150],{"trials":3167,"activeCount":96},[],{"trials":3169,"activeCount":96},[],{"trials":3171,"activeCount":96},[],{"intervention":3173,"totalTrials":170,"cells":3174},"Remifentanil",{"EARLY_PHASE1":3175,"PHASE1":3177,"PHASE2":3179,"PHASE3":3193,"PHASE4":3195,"NA":3197},{"trials":3176,"activeCount":96},[],{"trials":3178,"activeCount":96},[],{"trials":3180,"activeCount":96},[3181],{"nctId":3182,"briefTitle":3183,"status":972,"phases":3184,"primaryCompletion":3185,"completion":3185,"start":3186,"enrollment":3187,"conditions":3188,"interventions":3190},"NCT03066739","Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia",[85],"2024-12-10","2023-02-25",8,[3189],"Hyperalgesia",[3173,3191,3192],"Remifentanil+ Placebo","Remifentanil +ultra-low dose naloxone",{"trials":3194,"activeCount":96},[],{"trials":3196,"activeCount":96},[],{"trials":3198,"activeCount":96},[],{"intervention":3191,"totalTrials":170,"cells":3200},{"EARLY_PHASE1":3201,"PHASE1":3203,"PHASE2":3205,"PHASE3":3211,"PHASE4":3213,"NA":3215},{"trials":3202,"activeCount":96},[],{"trials":3204,"activeCount":96},[],{"trials":3206,"activeCount":96},[3207],{"nctId":3182,"briefTitle":3183,"status":972,"phases":3208,"primaryCompletion":3185,"completion":3185,"start":3186,"enrollment":3187,"conditions":3209,"interventions":3210},[85],[3189],[3173,3191,3192],{"trials":3212,"activeCount":96},[],{"trials":3214,"activeCount":96},[],{"trials":3216,"activeCount":96},[],{"intervention":3192,"totalTrials":170,"cells":3218},{"EARLY_PHASE1":3219,"PHASE1":3221,"PHASE2":3223,"PHASE3":3229,"PHASE4":3231,"NA":3233},{"trials":3220,"activeCount":96},[],{"trials":3222,"activeCount":96},[],{"trials":3224,"activeCount":96},[3225],{"nctId":3182,"briefTitle":3183,"status":972,"phases":3226,"primaryCompletion":3185,"completion":3185,"start":3186,"enrollment":3187,"conditions":3227,"interventions":3228},[85],[3189],[3173,3191,3192],{"trials":3230,"activeCount":96},[],{"trials":3232,"activeCount":96},[],{"trials":3234,"activeCount":96},[],{"intervention":3236,"totalTrials":170,"cells":3237},"Ropinirole",{"EARLY_PHASE1":3238,"PHASE1":3240,"PHASE2":3242,"PHASE3":3256,"PHASE4":3258,"NA":3260},{"trials":3239,"activeCount":96},[],{"trials":3241,"activeCount":96},[],{"trials":3243,"activeCount":96},[3244],{"nctId":3245,"briefTitle":3246,"status":150,"phases":3247,"primaryCompletion":3248,"completion":2983,"start":3249,"enrollment":3250,"conditions":3251,"interventions":3254},"NCT00221390","Trial of Ropinirole in Motor Recovery After Stroke",[85],"2007-02","2003-10",52,[3252,3253],"Cerebrovascular Accident","Hemiparesis",[3236,3255],"(vs.) Placebo + physical therapy",{"trials":3257,"activeCount":96},[],{"trials":3259,"activeCount":96},[],{"trials":3261,"activeCount":96},[],{"intervention":3255,"totalTrials":170,"cells":3263},{"EARLY_PHASE1":3264,"PHASE1":3266,"PHASE2":3268,"PHASE3":3274,"PHASE4":3276,"NA":3278},{"trials":3265,"activeCount":96},[],{"trials":3267,"activeCount":96},[],{"trials":3269,"activeCount":96},[3270],{"nctId":3245,"briefTitle":3246,"status":150,"phases":3271,"primaryCompletion":3248,"completion":2983,"start":3249,"enrollment":3250,"conditions":3272,"interventions":3273},[85],[3252,3253],[3236,3255],{"trials":3275,"activeCount":96},[],{"trials":3277,"activeCount":96},[],{"trials":3279,"activeCount":96},[],{"intervention":3281,"totalTrials":170,"cells":3282},"Pazopanib and Paclitaxel",{"EARLY_PHASE1":3283,"PHASE1":3285,"PHASE2":3287,"PHASE3":3300,"PHASE4":3302,"NA":3304},{"trials":3284,"activeCount":96},[],{"trials":3286,"activeCount":96},[],{"trials":3288,"activeCount":96},[3289],{"nctId":3290,"briefTitle":3291,"status":150,"phases":3292,"primaryCompletion":3293,"completion":3293,"start":3294,"enrollment":800,"conditions":3295,"interventions":3299},"NCT01107665","Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma",[85],"2018-02","2010-08",[3296,3297,3298],"Stage III Melanoma","Stage IV Melanoma","Unresectable Melanoma",[3281],{"trials":3301,"activeCount":96},[],{"trials":3303,"activeCount":96},[],{"trials":3305,"activeCount":96},[],{"intervention":3307,"totalTrials":170,"cells":3308},"Dual Growth Factor",{"EARLY_PHASE1":3309,"PHASE1":3311,"PHASE2":3313,"PHASE3":3323,"PHASE4":3325,"NA":3327},{"trials":3310,"activeCount":96},[],{"trials":3312,"activeCount":96},[],{"trials":3314,"activeCount":96},[3315],{"nctId":3316,"briefTitle":3317,"status":150,"phases":3318,"primaryCompletion":3006,"completion":3006,"start":3319,"enrollment":759,"conditions":3320,"interventions":3322},"NCT00362414","Beta-hCG + Erythropoietin in Acute Stroke",[85],"2006-08",[3321],"Acute Stroke",[3307],{"trials":3324,"activeCount":96},[],{"trials":3326,"activeCount":96},[],{"trials":3328,"activeCount":96},[],{"intervention":3330,"totalTrials":170,"cells":3331},"Topical Antiangiogenic",{"EARLY_PHASE1":3332,"PHASE1":3334,"PHASE2":3336,"PHASE3":3346,"PHASE4":3348,"NA":3350},{"trials":3333,"activeCount":96},[],{"trials":3335,"activeCount":96},[],{"trials":3337,"activeCount":96},[3338],{"nctId":3339,"briefTitle":3340,"status":2331,"phases":3341,"primaryCompletion":3342,"completion":3342,"start":3343,"enrollment":96,"conditions":3344,"interventions":3345},"NCT00969397","Combined Use of Pulsed Dye Laser and Topical Antiangiogenic Agents for Treatment of Port Wine Stain Birthmarks",[84,85],"2011-09","2009-11",[20],[3330],{"trials":3347,"activeCount":96},[],{"trials":3349,"activeCount":96},[],{"trials":3351,"activeCount":96},[],{"intervention":3353,"totalTrials":170,"cells":3354},"NRT",{"EARLY_PHASE1":3355,"PHASE1":3357,"PHASE2":3359,"PHASE3":3370,"PHASE4":3372,"NA":3374},{"trials":3356,"activeCount":96},[],{"trials":3358,"activeCount":96},[],{"trials":3360,"activeCount":96},[3361],{"nctId":3362,"briefTitle":3363,"status":150,"phases":3364,"primaryCompletion":3365,"completion":3365,"start":2834,"enrollment":3366,"conditions":3367,"interventions":3369},"NCT02823028","Twitter-enabled Mobile Messaging for Smoking Relapse Prevention (Tweet2Quit)",[85],"2022-09",980,[3368],"Smoking Cessation",[3353],{"trials":3371,"activeCount":96},[],{"trials":3373,"activeCount":96},[],{"trials":3375,"activeCount":96},[],{"intervention":3377,"totalTrials":170,"cells":3378},"bone marrow-derived mesenchymal stem cells",{"EARLY_PHASE1":3379,"PHASE1":3381,"PHASE2":3383,"PHASE3":3393,"PHASE4":3395,"NA":3397},{"trials":3380,"activeCount":96},[],{"trials":3382,"activeCount":96},[],{"trials":3384,"activeCount":96},[3385],{"nctId":3386,"briefTitle":3387,"status":2331,"phases":3388,"primaryCompletion":3389,"completion":3389,"start":3389,"enrollment":96,"conditions":3390,"interventions":3392},"NCT01849887","Safety of Escalating Doses of Intravenous Bone Marrow-Derived Mesenchymal Stem Cells in Patients With a New Ischemic Stroke",[84,85],"2016-01",[3391],"Ischemic Stroke",[3377],{"trials":3394,"activeCount":96},[],{"trials":3396,"activeCount":96},[],{"trials":3398,"activeCount":96},[],{"intervention":3400,"totalTrials":170,"cells":3401},"Fenofibrate",{"EARLY_PHASE1":3402,"PHASE1":3404,"PHASE2":3406,"PHASE3":3417,"PHASE4":3419,"NA":3421},{"trials":3403,"activeCount":96},[],{"trials":3405,"activeCount":96},[],{"trials":3407,"activeCount":96},[3408],{"nctId":3409,"briefTitle":3410,"status":150,"phases":3411,"primaryCompletion":3412,"completion":3412,"start":3413,"enrollment":1444,"conditions":3414,"interventions":3416},"NCT03515213","Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease",[85],"2021-08-31","2017-04-27",[3415],"Huntington Disease",[3400],{"trials":3418,"activeCount":96},[],{"trials":3420,"activeCount":96},[],{"trials":3422,"activeCount":96},[],{"intervention":686,"totalTrials":170,"cells":3424},{"EARLY_PHASE1":3425,"PHASE1":3427,"PHASE2":3429,"PHASE3":3435,"PHASE4":3437,"NA":3439},{"trials":3426,"activeCount":96},[],{"trials":3428,"activeCount":96},[],{"trials":3430,"activeCount":96},[3431],{"nctId":669,"briefTitle":670,"status":150,"phases":3432,"primaryCompletion":672,"completion":672,"start":673,"enrollment":674,"conditions":3433,"interventions":3434},[85],[15,676,677,678,679,680,681,682,683,684],[37,686,687,688],{"trials":3436,"activeCount":96},[],{"trials":3438,"activeCount":96},[],{"trials":3440,"activeCount":96},[],{"intervention":3442,"totalTrials":170,"cells":3443},"ADHD medication",{"EARLY_PHASE1":3444,"PHASE1":3446,"PHASE2":3448,"PHASE3":3459,"PHASE4":3461,"NA":3463},{"trials":3445,"activeCount":96},[],{"trials":3447,"activeCount":96},[],{"trials":3449,"activeCount":96},[3450],{"nctId":3451,"briefTitle":3452,"status":150,"phases":3453,"primaryCompletion":3454,"completion":3454,"start":3455,"enrollment":1046,"conditions":3456,"interventions":3458},"NCT00573859","The Reinforcing Mechanisms of Smoking in Adult ADHD",[84,85],"2010-06","2006-09",[3457],"ADHD",[3442],{"trials":3460,"activeCount":96},[],{"trials":3462,"activeCount":96},[],{"trials":3464,"activeCount":96},[],{"intervention":2938,"totalTrials":170,"cells":3466},{"EARLY_PHASE1":3467,"PHASE1":3469,"PHASE2":3471,"PHASE3":3477,"PHASE4":3479,"NA":3481},{"trials":3468,"activeCount":96},[],{"trials":3470,"activeCount":96},[],{"trials":3472,"activeCount":96},[3473],{"nctId":2931,"briefTitle":2932,"status":150,"phases":3474,"primaryCompletion":2934,"completion":2934,"start":2935,"enrollment":192,"conditions":3475,"interventions":3476},[85],[24],[2938,2913],{"trials":3478,"activeCount":96},[],{"trials":3480,"activeCount":96},[],{"trials":3482,"activeCount":96},[],{"intervention":3484,"totalTrials":170,"cells":3485},"Palmitoylethanolamide",{"EARLY_PHASE1":3486,"PHASE1":3488,"PHASE2":3490,"PHASE3":3503,"PHASE4":3505,"NA":3507},{"trials":3487,"activeCount":96},[],{"trials":3489,"activeCount":96},[],{"trials":3491,"activeCount":96},[3492],{"nctId":3493,"briefTitle":3494,"status":2331,"phases":3495,"primaryCompletion":3496,"completion":2561,"start":3497,"enrollment":96,"conditions":3498,"interventions":3502},"NCT05317676","Effect of Palmitoylethanolamide on Reducing Opioid Consumption for Below Knee Fracture Fixation",[85],"2024-12","2023-05",[3499,3500,3501],"Tibial Fractures","Fibula Fracture","Knee Fracture",[3484],{"trials":3504,"activeCount":96},[],{"trials":3506,"activeCount":96},[],{"trials":3508,"activeCount":96},[],{"intervention":698,"totalTrials":170,"cells":3510},{"EARLY_PHASE1":3511,"PHASE1":3513,"PHASE2":3515,"PHASE3":3521,"PHASE4":3523,"NA":3525},{"trials":3512,"activeCount":96},[],{"trials":3514,"activeCount":96},[],{"trials":3516,"activeCount":96},[3517],{"nctId":690,"briefTitle":691,"status":150,"phases":3518,"primaryCompletion":693,"completion":693,"start":694,"enrollment":695,"conditions":3519,"interventions":3520},[85],[15],[698,598,37,699,700,573,666],{"trials":3522,"activeCount":96},[],{"trials":3524,"activeCount":96},[],{"trials":3526,"activeCount":96},[],{"intervention":699,"totalTrials":170,"cells":3528},{"EARLY_PHASE1":3529,"PHASE1":3531,"PHASE2":3533,"PHASE3":3539,"PHASE4":3541,"NA":3543},{"trials":3530,"activeCount":96},[],{"trials":3532,"activeCount":96},[],{"trials":3534,"activeCount":96},[3535],{"nctId":690,"briefTitle":691,"status":150,"phases":3536,"primaryCompletion":693,"completion":693,"start":694,"enrollment":695,"conditions":3537,"interventions":3538},[85],[15],[698,598,37,699,700,573,666],{"trials":3540,"activeCount":96},[],{"trials":3542,"activeCount":96},[],{"trials":3544,"activeCount":96},[],{"intervention":3546,"totalTrials":170,"cells":3547},"Axitinib",{"EARLY_PHASE1":3548,"PHASE1":3550,"PHASE2":3552,"PHASE3":3567,"PHASE4":3569,"NA":3571},{"trials":3549,"activeCount":96},[],{"trials":3551,"activeCount":96},[],{"trials":3553,"activeCount":96},[3554],{"nctId":3555,"briefTitle":3556,"status":150,"phases":3557,"primaryCompletion":3558,"completion":3558,"start":3559,"enrollment":3560,"conditions":3561,"interventions":3566},"NCT01321437","Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma",[85],"2016-12","2011-12",11,[593,3562,3563,3564,3565],"Malignant Melanoma","Stage IIIA Melanoma","Stage IIIB Melanoma","Stage IIIC Melanoma",[3546],{"trials":3568,"activeCount":96},[],{"trials":3570,"activeCount":96},[],{"trials":3572,"activeCount":96},[],{"intervention":3574,"totalTrials":170,"cells":3575},"Abraxane",{"EARLY_PHASE1":3576,"PHASE1":3578,"PHASE2":3580,"PHASE3":3590,"PHASE4":3592,"NA":3594},{"trials":3577,"activeCount":96},[],{"trials":3579,"activeCount":96},[],{"trials":3581,"activeCount":96},[3582],{"nctId":3583,"briefTitle":3584,"status":972,"phases":3585,"primaryCompletion":2700,"completion":3454,"start":3586,"enrollment":1444,"conditions":3587,"interventions":3588},"NCT00319839","Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab",[85],"2006-03",[863],[3574,3589],"Cetuximab",{"trials":3591,"activeCount":96},[],{"trials":3593,"activeCount":96},[],{"trials":3595,"activeCount":96},[],{"intervention":3589,"totalTrials":170,"cells":3597},{"EARLY_PHASE1":3598,"PHASE1":3600,"PHASE2":3602,"PHASE3":3608,"PHASE4":3610,"NA":3612},{"trials":3599,"activeCount":96},[],{"trials":3601,"activeCount":96},[],{"trials":3603,"activeCount":96},[3604],{"nctId":3583,"briefTitle":3584,"status":972,"phases":3605,"primaryCompletion":2700,"completion":3454,"start":3586,"enrollment":1444,"conditions":3606,"interventions":3607},[85],[863],[3574,3589],{"trials":3609,"activeCount":96},[],{"trials":3611,"activeCount":96},[],{"trials":3613,"activeCount":96},[],{"intervention":3615,"totalTrials":170,"cells":3616},"Ranibizumab",{"EARLY_PHASE1":3617,"PHASE1":3619,"PHASE2":3628,"PHASE3":3630,"PHASE4":3632,"NA":3634},{"trials":3618,"activeCount":96},[],{"trials":3620,"activeCount":96},[3621],{"nctId":3622,"briefTitle":3623,"status":2331,"phases":3624,"primaryCompletion":3625,"completion":3625,"start":3006,"enrollment":96,"conditions":3626,"interventions":3627},"NCT00667472","Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks",[84],"2013-11",[27],[3615],{"trials":3629,"activeCount":96},[],{"trials":3631,"activeCount":96},[],{"trials":3633,"activeCount":96},[],{"trials":3635,"activeCount":96},[],{"intervention":3637,"totalTrials":170,"cells":3638},"Pomegranate",{"EARLY_PHASE1":3639,"PHASE1":3641,"PHASE2":3651,"PHASE3":3653,"PHASE4":3655,"NA":3657},{"trials":3640,"activeCount":96},[],{"trials":3642,"activeCount":96},[3643],{"nctId":3644,"briefTitle":3645,"status":1941,"phases":3646,"primaryCompletion":3454,"completion":3454,"start":3647,"enrollment":560,"conditions":3648,"interventions":3650},"NCT00381108","Study of the Effects of Pomegranate Tablets on Enlarged Prostates",[84],"2005-09",[3649],"Benign Prostatic Hyperplasia",[3637],{"trials":3652,"activeCount":96},[],{"trials":3654,"activeCount":96},[],{"trials":3656,"activeCount":96},[],{"trials":3658,"activeCount":96},[],{"intervention":3660,"totalTrials":170,"cells":3661},"Talaporfin sodium",{"EARLY_PHASE1":3662,"PHASE1":3664,"PHASE2":3675,"PHASE3":3677,"PHASE4":3679,"NA":3681},{"trials":3663,"activeCount":96},[],{"trials":3665,"activeCount":96},[3666],{"nctId":3667,"briefTitle":3668,"status":150,"phases":3669,"primaryCompletion":3670,"completion":3670,"start":3671,"enrollment":3672,"conditions":3673,"interventions":3674},"NCT01924273","Novel Treatment for Port Wine Stain Birthmarks",[84],"2017-07-03","2013-06",7,[27],[3660],{"trials":3676,"activeCount":96},[],{"trials":3678,"activeCount":96},[],{"trials":3680,"activeCount":96},[],{"trials":3682,"activeCount":96},[],{"intervention":1580,"totalTrials":170,"cells":3684},{"EARLY_PHASE1":3685,"PHASE1":3687,"PHASE2":3693,"PHASE3":3695,"PHASE4":3697,"NA":3699},{"trials":3686,"activeCount":96},[],{"trials":3688,"activeCount":96},[3689],{"nctId":1566,"briefTitle":1567,"status":150,"phases":3690,"primaryCompletion":1569,"completion":1570,"start":1571,"enrollment":25,"conditions":3691,"interventions":3692},[84],[1573,1574,1575,1576,1577,1578],[1559,1580],{"trials":3694,"activeCount":96},[],{"trials":3696,"activeCount":96},[],{"trials":3698,"activeCount":96},[],{"trials":3700,"activeCount":96},[],{"intervention":3702,"totalTrials":170,"cells":3703},"Laser and rapamycin versus laser alone",{"EARLY_PHASE1":3704,"PHASE1":3706,"PHASE2":3714,"PHASE3":3716,"PHASE4":3718,"NA":3720},{"trials":3705,"activeCount":96},[],{"trials":3707,"activeCount":96},[3708],{"nctId":3709,"briefTitle":3710,"status":150,"phases":3711,"primaryCompletion":3389,"completion":3389,"start":2588,"enrollment":1499,"conditions":3712,"interventions":3713},"NCT00830466","A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks.",[84],[20],[3702],{"trials":3715,"activeCount":96},[],{"trials":3717,"activeCount":96},[],{"trials":3719,"activeCount":96},[],{"trials":3721,"activeCount":96},[],{"intervention":3723,"totalTrials":170,"cells":3724},"Disulfiram",{"EARLY_PHASE1":3725,"PHASE1":3727,"PHASE2":3738,"PHASE3":3740,"PHASE4":3742,"NA":3744},{"trials":3726,"activeCount":96},[],{"trials":3728,"activeCount":96},[3729],{"nctId":3730,"briefTitle":3731,"status":972,"phases":3732,"primaryCompletion":3733,"completion":3733,"start":3455,"enrollment":9,"conditions":3734,"interventions":3736},"NCT00571116","Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy",[84],"2012-08",[3735],"Metastatic Melanoma",[3723,3737],"Arsenic trioxide",{"trials":3739,"activeCount":96},[],{"trials":3741,"activeCount":96},[],{"trials":3743,"activeCount":96},[],{"trials":3745,"activeCount":96},[],{"intervention":3737,"totalTrials":170,"cells":3747},{"EARLY_PHASE1":3748,"PHASE1":3750,"PHASE2":3756,"PHASE3":3758,"PHASE4":3760,"NA":3762},{"trials":3749,"activeCount":96},[],{"trials":3751,"activeCount":96},[3752],{"nctId":3730,"briefTitle":3731,"status":972,"phases":3753,"primaryCompletion":3733,"completion":3733,"start":3455,"enrollment":9,"conditions":3754,"interventions":3755},[84],[3735],[3723,3737],{"trials":3757,"activeCount":96},[],{"trials":3759,"activeCount":96},[],{"trials":3761,"activeCount":96},[],{"trials":3763,"activeCount":96},[],{"intervention":3765,"totalTrials":170,"cells":3766},"autologous bone marrow mononuclear cell transfusion",{"EARLY_PHASE1":3767,"PHASE1":3769,"PHASE2":3779,"PHASE3":3781,"PHASE4":3783,"NA":3785},{"trials":3768,"activeCount":96},[],{"trials":3770,"activeCount":96},[3771],{"nctId":3772,"briefTitle":3773,"status":2331,"phases":3774,"primaryCompletion":2424,"completion":2424,"start":3389,"enrollment":96,"conditions":3775,"interventions":3777},"NCT00908856","Autologous Cell Therapy After Stroke",[84],[3776],"Stroke",[3765,3778],"marrow stromal cells",{"trials":3780,"activeCount":96},[],{"trials":3782,"activeCount":96},[],{"trials":3784,"activeCount":96},[],{"trials":3786,"activeCount":96},[],{"intervention":3778,"totalTrials":170,"cells":3788},{"EARLY_PHASE1":3789,"PHASE1":3791,"PHASE2":3797,"PHASE3":3799,"PHASE4":3801,"NA":3803},{"trials":3790,"activeCount":96},[],{"trials":3792,"activeCount":96},[3793],{"nctId":3772,"briefTitle":3773,"status":2331,"phases":3794,"primaryCompletion":2424,"completion":2424,"start":3389,"enrollment":96,"conditions":3795,"interventions":3796},[84],[3776],[3765,3778],{"trials":3798,"activeCount":96},[],{"trials":3800,"activeCount":96},[],{"trials":3802,"activeCount":96},[],{"trials":3804,"activeCount":96},[],{"intervention":3806,"totalTrials":170,"cells":3807},"calcium hydroxylapatite",{"EARLY_PHASE1":3808,"PHASE1":3810,"PHASE2":3821,"PHASE3":3823,"PHASE4":3825,"NA":3827},{"trials":3809,"activeCount":96},[],{"trials":3811,"activeCount":96},[3812],{"nctId":3813,"briefTitle":3814,"status":150,"phases":3815,"primaryCompletion":3816,"completion":3816,"start":3817,"enrollment":560,"conditions":3818,"interventions":3820},"NCT04176068","Combined Focused Ultrasound and Calcium Hydroxylapatitie Filler for Skin Laxity and Volume Restoration",[84],"2021-12-01","2019-04-19",[3819],"Skin Laxity",[3806],{"trials":3822,"activeCount":96},[],{"trials":3824,"activeCount":96},[],{"trials":3826,"activeCount":96},[],{"trials":3828,"activeCount":96},[],{"intervention":3830,"totalTrials":170,"cells":3831},"Pembrolizumab Injection [Keytruda]",{"EARLY_PHASE1":3832,"PHASE1":3834,"PHASE2":3845,"PHASE3":3847,"PHASE4":3849,"NA":3851},{"trials":3833,"activeCount":96},[],{"trials":3835,"activeCount":96},[3836],{"nctId":3837,"briefTitle":3838,"status":2331,"phases":3839,"primaryCompletion":3840,"completion":3840,"start":1943,"enrollment":96,"conditions":3841,"interventions":3844},"NCT03189186","Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas",[84],"2018-10-17",[3842,3843],"Renal Cell Carcinoma","Metastatic Kidney Cancer",[3830],{"trials":3846,"activeCount":96},[],{"trials":3848,"activeCount":96},[],{"trials":3850,"activeCount":96},[],{"trials":3852,"activeCount":96},[],{"intervention":3854,"totalTrials":170,"cells":3855},"Rapamycin Treatment of Port Wine Stain",{"EARLY_PHASE1":3856,"PHASE1":3858,"PHASE2":3868,"PHASE3":3870,"PHASE4":3872,"NA":3874},{"trials":3857,"activeCount":96},[],{"trials":3859,"activeCount":96},[3860],{"nctId":3861,"briefTitle":3710,"status":150,"phases":3862,"primaryCompletion":3863,"completion":3863,"start":3864,"enrollment":3865,"conditions":3866,"interventions":3867},"NCT00800722",[84],"2014-06","2008-11",21,[20],[3854],{"trials":3869,"activeCount":96},[],{"trials":3871,"activeCount":96},[],{"trials":3873,"activeCount":96},[],{"trials":3875,"activeCount":96},[],{"intervention":3877,"totalTrials":170,"cells":3878},"Resveratrol",{"EARLY_PHASE1":3879,"PHASE1":3881,"PHASE2":3890,"PHASE3":3892,"PHASE4":3894,"NA":3896},{"trials":3880,"activeCount":96},[],{"trials":3882,"activeCount":96},[3883],{"nctId":3884,"briefTitle":3885,"status":150,"phases":3886,"primaryCompletion":2588,"completion":3133,"start":3887,"enrollment":3560,"conditions":3888,"interventions":3889},"NCT00256334","Resveratrol for Patients With Colon Cancer",[84],"2005-07",[2899,18],[3877],{"trials":3891,"activeCount":96},[],{"trials":3893,"activeCount":96},[],{"trials":3895,"activeCount":96},[],{"trials":3897,"activeCount":96},[],{"intervention":3899,"totalTrials":170,"cells":3900},"Sirolimus",{"EARLY_PHASE1":3901,"PHASE1":3912,"PHASE2":3914,"PHASE3":3916,"PHASE4":3918,"NA":3920},{"trials":3902,"activeCount":96},[3903],{"nctId":3904,"briefTitle":3905,"status":972,"phases":3906,"primaryCompletion":3907,"completion":3907,"start":3908,"enrollment":606,"conditions":3909,"interventions":3911},"NCT01313923","Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus",[83],"2014-10","2011-02",[3910],"Pemphigus",[3899],{"trials":3913,"activeCount":96},[],{"trials":3915,"activeCount":96},[],{"trials":3917,"activeCount":96},[],{"trials":3919,"activeCount":96},[],{"trials":3921,"activeCount":96},[],{"intervention":3923,"totalTrials":170,"cells":3924},"NAC",{"EARLY_PHASE1":3925,"PHASE1":3937,"PHASE2":3939,"PHASE3":3941,"PHASE4":3943,"NA":3945},{"trials":3926,"activeCount":96},[3927],{"nctId":3928,"briefTitle":3929,"status":2331,"phases":3930,"primaryCompletion":3931,"completion":3932,"start":3933,"enrollment":96,"conditions":3934,"interventions":3936},"NCT05371288","The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19",[83],"2025-09","2025-11","2025-06",[3935],"COVID-19",[3923],{"trials":3938,"activeCount":96},[],{"trials":3940,"activeCount":96},[],{"trials":3942,"activeCount":96},[],{"trials":3944,"activeCount":96},[],{"trials":3946,"activeCount":96},[],{"intervention":3948,"totalTrials":170,"cells":3949},"IVIg",{"EARLY_PHASE1":3950,"PHASE1":3962,"PHASE2":3964,"PHASE3":3966,"PHASE4":3968,"NA":3970},{"trials":3951,"activeCount":96},[3952],{"nctId":3953,"briefTitle":3954,"status":150,"phases":3955,"primaryCompletion":3956,"completion":3956,"start":3957,"enrollment":3958,"conditions":3959,"interventions":3961},"NCT01841619","IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus",[83],"2014-11","2013-03",16,[3960],"Cutaneous Lupus Erythematosus",[3948],{"trials":3963,"activeCount":96},[],{"trials":3965,"activeCount":96},[],{"trials":3967,"activeCount":96},[],{"trials":3969,"activeCount":96},[],{"trials":3971,"activeCount":96},[],{"intervention":3973,"totalTrials":170,"cells":3974},"Tretinoin cream 0.1%",{"EARLY_PHASE1":3975,"PHASE1":3984,"PHASE2":3986,"PHASE3":3988,"PHASE4":3990,"NA":3992},{"trials":3976,"activeCount":96},[3977],{"nctId":3978,"briefTitle":3979,"status":150,"phases":3980,"primaryCompletion":3558,"completion":3558,"start":2066,"enrollment":759,"conditions":3981,"interventions":3983},"NCT02410980","Assessing the Effects of Tretinoin Cream on Human Skin With Optical Imaging Technologies",[83],[3982],"Collagen Fibril Alteration",[3973],{"trials":3985,"activeCount":96},[],{"trials":3987,"activeCount":96},[],{"trials":3989,"activeCount":96},[],{"trials":3991,"activeCount":96},[],{"trials":3993,"activeCount":96},[],{"intervention":3995,"totalTrials":170,"cells":3996},"Crisaborole 2% Top Oint",{"EARLY_PHASE1":3997,"PHASE1":4010,"PHASE2":4012,"PHASE3":4014,"PHASE4":4016,"NA":4018},{"trials":3998,"activeCount":96},[3999],{"nctId":4000,"briefTitle":4001,"status":150,"phases":4002,"primaryCompletion":4003,"completion":4003,"start":4004,"enrollment":560,"conditions":4005,"interventions":4008},"NCT04800185","Characterizing Skin Microbiome Change in Atopic Dermatitis",[83],"2022-04-30","2021-03-23",[4006,4007],"Atopic Dermatitis","Atopic Dermatitis Eczema",[3995,4009],"Skin Microbiome Swabs",{"trials":4011,"activeCount":96},[],{"trials":4013,"activeCount":96},[],{"trials":4015,"activeCount":96},[],{"trials":4017,"activeCount":96},[],{"trials":4019,"activeCount":96},[],{"intervention":4009,"totalTrials":170,"cells":4021},{"EARLY_PHASE1":4022,"PHASE1":4028,"PHASE2":4030,"PHASE3":4032,"PHASE4":4034,"NA":4036},{"trials":4023,"activeCount":96},[4024],{"nctId":4000,"briefTitle":4001,"status":150,"phases":4025,"primaryCompletion":4003,"completion":4003,"start":4004,"enrollment":560,"conditions":4026,"interventions":4027},[83],[4006,4007],[3995,4009],{"trials":4029,"activeCount":96},[],{"trials":4031,"activeCount":96},[],{"trials":4033,"activeCount":96},[],{"trials":4035,"activeCount":96},[],{"trials":4037,"activeCount":96},[],{"intervention":4039,"totalTrials":170,"cells":4040},"Fecal Microbiota Transplantation",{"EARLY_PHASE1":4041,"PHASE1":4052,"PHASE2":4054,"PHASE3":4056,"PHASE4":4058,"NA":4060},{"trials":4042,"activeCount":96},[4043],{"nctId":4044,"briefTitle":4045,"status":150,"phases":4046,"primaryCompletion":4047,"completion":4048,"start":4049,"enrollment":192,"conditions":4050,"interventions":4051},"NCT03050515","Fecal Microbiota Transplantation for the Treatment of Recurrent Urinary Tract Infections",[83],"2019-06-30","2020-02-23","2018-02-05",[471],[4039],{"trials":4053,"activeCount":96},[],{"trials":4055,"activeCount":96},[],{"trials":4057,"activeCount":96},[],{"trials":4059,"activeCount":96},[],{"trials":4061,"activeCount":96},[],{"intervention":4063,"totalTrials":92,"cells":4064},"Vesicare",{"EARLY_PHASE1":4065,"PHASE1":4067,"PHASE2":4069,"PHASE3":4071,"PHASE4":4073,"NA":4075},{"trials":4066,"activeCount":96},[],{"trials":4068,"activeCount":96},[],{"trials":4070,"activeCount":96},[],{"trials":4072,"activeCount":96},[],{"trials":4074,"activeCount":96},[],{"trials":4076,"activeCount":96},[4077,4086],{"nctId":4078,"briefTitle":4079,"status":150,"phases":4080,"primaryCompletion":4081,"completion":4081,"start":4082,"enrollment":165,"conditions":4083,"interventions":4085},"NCT01215721","Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)",[88],"2013-05","2010-10",[4084],"Urinary Incontinence",[4063],{"nctId":4087,"briefTitle":4088,"status":972,"phases":4089,"primaryCompletion":4090,"completion":4091,"start":4092,"enrollment":16,"conditions":4093,"interventions":4095},"NCT00581061","Study to Determine Effects of Vesicare on Return to Continence Post- Radical Prostatectomy",[88],"2009-02","2010-02","2008-06",[4094],"Incontinence",[4063],{"intervention":4097,"totalTrials":170,"cells":4098},"COVID-19 Androgen Sensitivity Test",{"EARLY_PHASE1":4099,"PHASE1":4101,"PHASE2":4103,"PHASE3":4105,"PHASE4":4107,"NA":4109},{"trials":4100,"activeCount":96},[],{"trials":4102,"activeCount":96},[],{"trials":4104,"activeCount":96},[],{"trials":4106,"activeCount":96},[],{"trials":4108,"activeCount":96},[],{"trials":4110,"activeCount":96},[4111],{"nctId":4112,"briefTitle":4113,"status":2331,"phases":4114,"primaryCompletion":3816,"completion":4115,"start":4116,"enrollment":96,"conditions":4117,"interventions":4120},"NCT04530500","COVID-19 In-vitro Diagnostic Test and Androgen Receptor Gene Expression",[],"2023-12-01","2020-08-13",[4118,4119],"Covid19","Androgen Receptor Gene Overexpression",[4097],{"intervention":4122,"totalTrials":170,"cells":4123},"Imiquimod",{"EARLY_PHASE1":4124,"PHASE1":4126,"PHASE2":4128,"PHASE3":4130,"PHASE4":4132,"NA":4134},{"trials":4125,"activeCount":96},[],{"trials":4127,"activeCount":96},[],{"trials":4129,"activeCount":96},[],{"trials":4131,"activeCount":96},[],{"trials":4133,"activeCount":96},[],{"trials":4135,"activeCount":96},[4136],{"nctId":4137,"briefTitle":4138,"status":150,"phases":4139,"primaryCompletion":3733,"completion":3733,"start":4140,"enrollment":1046,"conditions":4141,"interventions":4142},"NCT00585247","Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks",[88],"2006-11",[20],[4122],{"intervention":4144,"totalTrials":170,"cells":4145},"Vaginal ERT",{"EARLY_PHASE1":4146,"PHASE1":4148,"PHASE2":4150,"PHASE3":4152,"PHASE4":4154,"NA":4156},{"trials":4147,"activeCount":96},[],{"trials":4149,"activeCount":96},[],{"trials":4151,"activeCount":96},[],{"trials":4153,"activeCount":96},[],{"trials":4155,"activeCount":96},[],{"trials":4157,"activeCount":96},[4158],{"nctId":4159,"briefTitle":4160,"status":2331,"phases":4161,"primaryCompletion":2779,"completion":2779,"start":2521,"enrollment":96,"conditions":4162,"interventions":4164},"NCT01123135","The Effect of Vaginal Estrogen Cream on Subjective and Objective Symptoms of Urodynamic Stress Incontinence",[88],[4163],"Stress Urinary Incontinence",[4144],{"intervention":4166,"totalTrials":170,"cells":4167},"Nifedipine",{"EARLY_PHASE1":4168,"PHASE1":4170,"PHASE2":4172,"PHASE3":4174,"PHASE4":4176,"NA":4178},{"trials":4169,"activeCount":96},[],{"trials":4171,"activeCount":96},[],{"trials":4173,"activeCount":96},[],{"trials":4175,"activeCount":96},[],{"trials":4177,"activeCount":96},[],{"trials":4179,"activeCount":96},[4180],{"nctId":4181,"briefTitle":4182,"status":150,"phases":4183,"primaryCompletion":4184,"completion":4184,"start":4185,"enrollment":4186,"conditions":4187,"interventions":4189},"NCT03129945","Comparison of Nifedipine Versus Indomethacin for Acute Preterm Labor",[88],"2019-04-18","2017-01-17",36,[4188],"Obstetric Labor, Premature",[4166,4190],"Indomethacin",{"intervention":4190,"totalTrials":170,"cells":4192},{"EARLY_PHASE1":4193,"PHASE1":4195,"PHASE2":4197,"PHASE3":4199,"PHASE4":4201,"NA":4203},{"trials":4194,"activeCount":96},[],{"trials":4196,"activeCount":96},[],{"trials":4198,"activeCount":96},[],{"trials":4200,"activeCount":96},[],{"trials":4202,"activeCount":96},[],{"trials":4204,"activeCount":96},[4205],{"nctId":4181,"briefTitle":4182,"status":150,"phases":4206,"primaryCompletion":4184,"completion":4184,"start":4185,"enrollment":4186,"conditions":4207,"interventions":4208},[88],[4188],[4166,4190],{"intervention":4210,"totalTrials":170,"cells":4211},"ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block",{"EARLY_PHASE1":4212,"PHASE1":4214,"PHASE2":4216,"PHASE3":4218,"PHASE4":4220,"NA":4222},{"trials":4213,"activeCount":96},[],{"trials":4215,"activeCount":96},[],{"trials":4217,"activeCount":96},[],{"trials":4219,"activeCount":96},[],{"trials":4221,"activeCount":96},[],{"trials":4223,"activeCount":96},[4224],{"nctId":4225,"briefTitle":4226,"status":150,"phases":4227,"primaryCompletion":4228,"completion":4229,"start":4230,"enrollment":4231,"conditions":4232,"interventions":4234},"NCT02276495","Can Single-Injection Adductor Canal Blocks Improve PostOp Pain Relief in Patients Undergoing Total Knee Arthroplasty?",[88],"2020-06-20","2024-09-30","2015-01-01",55,[4233],"Pain Management",[4210,4235],"Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline",{"intervention":4235,"totalTrials":170,"cells":4237},{"EARLY_PHASE1":4238,"PHASE1":4240,"PHASE2":4242,"PHASE3":4244,"PHASE4":4246,"NA":4248},{"trials":4239,"activeCount":96},[],{"trials":4241,"activeCount":96},[],{"trials":4243,"activeCount":96},[],{"trials":4245,"activeCount":96},[],{"trials":4247,"activeCount":96},[],{"trials":4249,"activeCount":96},[4250],{"nctId":4225,"briefTitle":4226,"status":150,"phases":4251,"primaryCompletion":4228,"completion":4229,"start":4230,"enrollment":4231,"conditions":4252,"interventions":4253},[88],[4233],[4210,4235],{"intervention":4255,"totalTrials":170,"cells":4256},"Combined Photodynamic & Pulsed Dye Laser Treatment",{"EARLY_PHASE1":4257,"PHASE1":4259,"PHASE2":4261,"PHASE3":4263,"PHASE4":4265,"NA":4267},{"trials":4258,"activeCount":96},[],{"trials":4260,"activeCount":96},[],{"trials":4262,"activeCount":96},[],{"trials":4264,"activeCount":96},[],{"trials":4266,"activeCount":96},[],{"trials":4268,"activeCount":96},[4269],{"nctId":4270,"briefTitle":4271,"status":150,"phases":4272,"primaryCompletion":3907,"completion":3907,"start":4273,"enrollment":2026,"conditions":4274,"interventions":4276},"NCT00556946","Combined Photodynamic and Pulsed Dye Laser Treatment of Port Wine Stains",[88],"2005-08",[4275],"Port Wine Stains",[4255],{"intervention":4278,"totalTrials":170,"cells":4279},"Arm 2: Decolonization",{"EARLY_PHASE1":4280,"PHASE1":4282,"PHASE2":4284,"PHASE3":4286,"PHASE4":4288,"NA":4290},{"trials":4281,"activeCount":96},[],{"trials":4283,"activeCount":96},[],{"trials":4285,"activeCount":96},[],{"trials":4287,"activeCount":96},[],{"trials":4289,"activeCount":96},[],{"trials":4291,"activeCount":96},[4292],{"nctId":4293,"briefTitle":4294,"status":150,"phases":4295,"primaryCompletion":4296,"completion":4296,"start":4297,"enrollment":2426,"conditions":4298,"interventions":4302},"NCT02063867","Active Bathing to Eliminate Infection (ABATE Infection) Trial",[88],"2019-02","2014-04",[4299,4300,4301],"Healthcare Associated Infections","Methicillin Resistant Staphylococcus Aureus","Multi Drug Resistant Organisms",[4278],{"intervention":4304,"totalTrials":170,"cells":4305},"Experimental: methylphenidate treatment",{"EARLY_PHASE1":4306,"PHASE1":4308,"PHASE2":4310,"PHASE3":4312,"PHASE4":4314,"NA":4316},{"trials":4307,"activeCount":96},[],{"trials":4309,"activeCount":96},[],{"trials":4311,"activeCount":96},[],{"trials":4313,"activeCount":96},[],{"trials":4315,"activeCount":96},[],{"trials":4317,"activeCount":96},[4318],{"nctId":4319,"briefTitle":4320,"status":150,"phases":4321,"primaryCompletion":4322,"completion":3133,"start":4323,"enrollment":4324,"conditions":4325,"interventions":4327},"NCT00580814","Brain Dopamine Function in Adults With ADHD",[88],"2009-03","2006-02",75,[4326],"Attention Deficit Hyperactivity Disorder",[4304],{"intervention":4329,"totalTrials":170,"cells":4330},"18F-fallypride",{"EARLY_PHASE1":4331,"PHASE1":4333,"PHASE2":4335,"PHASE3":4337,"PHASE4":4339,"NA":4341},{"trials":4332,"activeCount":96},[],{"trials":4334,"activeCount":96},[],{"trials":4336,"activeCount":96},[],{"trials":4338,"activeCount":96},[],{"trials":4340,"activeCount":96},[],{"trials":4342,"activeCount":96},[4343],{"nctId":4344,"briefTitle":4345,"status":150,"phases":4346,"primaryCompletion":4347,"completion":4347,"start":673,"enrollment":895,"conditions":4348,"interventions":4350},"NCT00633763","PET-CT Scan Method to Monitor Pancreatic B-Cell Loss in Diabetes Mellitus",[],"2008-07",[4349],"Type1 Diabetes Mellitus",[4329,4329],{"intervention":4352,"totalTrials":170,"cells":4353},"Fecal Microbial Transplantation",{"EARLY_PHASE1":4354,"PHASE1":4356,"PHASE2":4358,"PHASE3":4360,"PHASE4":4362,"NA":4364},{"trials":4355,"activeCount":96},[],{"trials":4357,"activeCount":96},[],{"trials":4359,"activeCount":96},[],{"trials":4361,"activeCount":96},[],{"trials":4363,"activeCount":96},[],{"trials":4365,"activeCount":96},[4366],{"nctId":4367,"briefTitle":4368,"status":150,"phases":4369,"primaryCompletion":4370,"completion":4370,"start":4297,"enrollment":2188,"conditions":4371,"interventions":4373},"NCT02326636","Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection",[],"2018-10-26",[4372],"Clostridium Difficile Infection",[4352],{"intervention":4375,"totalTrials":170,"cells":4376},"MRSA Decolonization",{"EARLY_PHASE1":4377,"PHASE1":4379,"PHASE2":4381,"PHASE3":4383,"PHASE4":4385,"NA":4387},{"trials":4378,"activeCount":96},[],{"trials":4380,"activeCount":96},[],{"trials":4382,"activeCount":96},[],{"trials":4384,"activeCount":96},[],{"trials":4386,"activeCount":96},[],{"trials":4388,"activeCount":96},[4389],{"nctId":4390,"briefTitle":4391,"status":150,"phases":4392,"primaryCompletion":4393,"completion":4393,"start":2520,"enrollment":4394,"conditions":4395,"interventions":4397},"NCT01209234","Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance",[88],"2019-01",2140,[4396],"Methicillin-resistant Staphylococcus Aureus",[4375],{"intervention":4399,"totalTrials":170,"cells":4400},"Fourstar® granule, 90 day and 180 day briquettes Bti\u002FBs",{"EARLY_PHASE1":4401,"PHASE1":4403,"PHASE2":4405,"PHASE3":4407,"PHASE4":4409,"NA":4411},{"trials":4402,"activeCount":96},[],{"trials":4404,"activeCount":96},[],{"trials":4406,"activeCount":96},[],{"trials":4408,"activeCount":96},[],{"trials":4410,"activeCount":96},[],{"trials":4412,"activeCount":96},[4413],{"nctId":4414,"briefTitle":4415,"status":150,"phases":4416,"primaryCompletion":4417,"completion":4417,"start":661,"enrollment":4418,"conditions":4419,"interventions":4421},"NCT02392832","Evaluation of Long-Lasting Microbial Larvicides in Reducing Malaria Transmission and Clinical Malaria Incidence",[88],"2019-09",240000,[4420],"Malaria",[4399],{"intervention":4423,"totalTrials":170,"cells":4424},"Pudendal block",{"EARLY_PHASE1":4425,"PHASE1":4427,"PHASE2":4429,"PHASE3":4431,"PHASE4":4433,"NA":4435},{"trials":4426,"activeCount":96},[],{"trials":4428,"activeCount":96},[],{"trials":4430,"activeCount":96},[],{"trials":4432,"activeCount":96},[],{"trials":4434,"activeCount":96},[],{"trials":4436,"activeCount":96},[4437],{"nctId":4438,"briefTitle":4439,"status":150,"phases":4440,"primaryCompletion":4441,"completion":4442,"start":3133,"enrollment":165,"conditions":4443,"interventions":4445},"NCT00928564","Addition of Pudendal Blocks to Pelvic Floor Physical Therapy for the Treatment of Pelvic Floor Tension Myalgia",[88],"2015-12","2016-05",[4444],"Pelvic Floor Muscle Spasm",[4423],{"intervention":4447,"totalTrials":170,"cells":4448},"Nicotine",{"EARLY_PHASE1":4449,"PHASE1":4451,"PHASE2":4453,"PHASE3":4455,"PHASE4":4457,"NA":4459},{"trials":4450,"activeCount":96},[],{"trials":4452,"activeCount":96},[],{"trials":4454,"activeCount":96},[],{"trials":4456,"activeCount":96},[],{"trials":4458,"activeCount":96},[],{"trials":4460,"activeCount":96},[4461],{"nctId":4462,"briefTitle":4463,"status":150,"phases":4464,"primaryCompletion":4465,"completion":4465,"start":4273,"enrollment":154,"conditions":4466,"interventions":4467},"NCT00573248","Nicotine and Behavior in Adult ADHD",[88],"2009-12",[3457],[4447],{"intervention":4469,"totalTrials":170,"cells":4470},"irinotecan hydrochloride",{"EARLY_PHASE1":4471,"PHASE1":4473,"PHASE2":4475,"PHASE3":4477,"PHASE4":4479,"NA":4481},{"trials":4472,"activeCount":96},[],{"trials":4474,"activeCount":96},[],{"trials":4476,"activeCount":96},[],{"trials":4478,"activeCount":96},[],{"trials":4480,"activeCount":96},[],{"trials":4482,"activeCount":96},[4483],{"nctId":4484,"briefTitle":4485,"status":2331,"phases":4486,"primaryCompletion":4487,"completion":4488,"start":4489,"enrollment":96,"conditions":4490,"interventions":4494},"NCT01939483","A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases",[88],"2017-08","2018-08","2012-12",[4491,4492,678,4493],"Central Nervous System Metastases","Male Breast Cancer","Stage IV Breast Cancer",[4469],{"intervention":4496,"totalTrials":170,"cells":4497},"drawing blood sample",{"EARLY_PHASE1":4498,"PHASE1":4500,"PHASE2":4502,"PHASE3":4504,"PHASE4":4506,"NA":4508},{"trials":4499,"activeCount":96},[],{"trials":4501,"activeCount":96},[],{"trials":4503,"activeCount":96},[],{"trials":4505,"activeCount":96},[],{"trials":4507,"activeCount":96},[],{"trials":4509,"activeCount":96},[4510],{"nctId":4511,"briefTitle":4512,"status":972,"phases":4513,"primaryCompletion":2588,"completion":3559,"start":4514,"enrollment":165,"conditions":4515,"interventions":4517},"NCT00762398","Evaluation of the Accuracy and Precision of the Masimo Labs Pulse-Hemoglobin-Meter Monitor in Surgical Patients",[],"2008-09",[4516],"Adult Patient Undergoing Major Surgery",[4496]]